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Lactate	  Biosensor	  to	  Monitor	  Glioblastoma	  Multiforme	   	  
Abstract	  —	  A	  lactate	  biosensor	  was	  designed	  to	  monitor	  tumor	  size	  in	  patients	  with	  Glioblastoma	  
Multiforme,	  an	  aggressive	  form	  of	  brain	  tumor.	  Current	  monitoring	  methods	  are	  expensive	  and	  not	  
conducive	  to	  frequent	  use,	  creating	  a	  need	  for	  a	  biosensor	  to	  frequently	  monitor	  GBM	  tumor	  size.	  This	  
biosensor	  was	  composed	  of	  polypyrrole	  (PPY)	  and	  polyaniline	  (PANI)	  layers	  with	  lactate	  oxidase	  (LOX)	  
cross-­‐linked	  to	  the	  surface	  using	  glutaraldehyde.	  The	  components	  of	  the	  biosensor	  were	  tested	  
iteratively.	  The	  biosensor	  is	  able	  to	  detect	  increases	  in	  lactate	  concentration.	  It	  is	  has	  a	  higher	  
maximum	  current	  than	  other	  designs	  and	  is	  able	  to	  detect	  greater	  presence	  of	  lactate.	  More	  testing	  is	  
needed	  in	  order	  to	  continue	  validation	  of	  the	  biosensor	  and	  extend	  the	  technology	  to	  other	  
metabolites.	  
I.	  	  INTRODUCTION	  
Glioblastoma	  Multiforme	  (GBM)	  is	  an	  extremely	  aggressive	  form	  of	  brain	  cancer	  that	  has	  a	  three-­‐
year	  survival	  rate	  of	  less	  than	  two	  percent	  [1].	  Treatment	  options	  for	  GBM	  patients	  are	  surgery,	  
chemotherapy	  and	  radiotherapy.	  Current	  methods	  used	  to	  monitor	  tumor	  progression	  are	  Magnetic	  
Resonance	  Imaging	  (MRI)	  and	  Computed	  Tomography	  (CT)	  scans.	  These	  methods	  have	  limitations	  and	  
are	  not	  conducive	  for	  frequent	  use.	  Therefore,	  there	  is	  a	  critical	  need	  to	  develop	  a	  method	  to	  frequently	  
monitor	  tumor	  size	  in	  GBM	  patients	  to	  determine	  treatment	  efficacy.	  	  
This	  project	  exploits	  differences	  in	  cellular	  metabolism	  found	  in	  tumor	  cells.	  In	  healthy	  cells,	  glucose	  
is	  broken	  down	  into	  pyruvate	  and	  enters	  the	  mitochondria	  and	  causes	  the	  production	  of	  36	  molecules	  of	  
adenosine	  triphosphate	  (ATP)	  per	  molecule	  of	  glucose.	  However,	  in	  cancerous	  cells,	  pyruvate	  is	  broken	  
down	  into	  lactate	  to	  generate	  four	  molecules	  of	  ATP	  [2][3][4].	  The	  increase	  in	  lactate	  production	  of	  
tumor	  cells	  can	  be	  used	  to	  monitor	  tumor	  size,	  as	  more	  tumor	  cells	  will	  create	  an	  elevated	  level	  of	  
lactate.	  	  
A	  biosensor	  was	  designed	  to	  monitor	  the	  progression	  of	  GBM	  via	  lactate	  concentration.	  In	  order	  to	  
measure	  lactate	  concentration,	  an	  enzyme,	  lactate	  oxidase	  (LOX),	  is	  required	  to	  break	  down	  the	  lactate	  
into	  hydrogen	  peroxide	  and	  then	  into	  free	  electrons.	  	  𝐿𝑎𝑐𝑡𝑎𝑡𝑒 +   𝑂! !"# 𝑃𝑦𝑟𝑢𝑣𝑎𝑡𝑒 +  	  𝐻!0! 	  
	   𝐻!𝑂! !"#$%&' 2𝐻! + 𝑂! + 2𝑒! 	  
	  
The	  signal	  measured	  by	  the	  biosensor	  is	  the	  current	  created	  by	  these	  electrons	  at	  the	  electrode	  
surface.	  The	  biosensor	  must	  be	  able	  to	  sense	  lactate	  levels	  without	  interference	  from	  other	  molecules.	  It	  
must	  also	  be	  sensitive	  enough	  to	  detect	  the	  levels	  of	  lactate	  created	  by	  a	  GBM	  tumor.	  The	  biosensor	  
must	  be	  biocompatible	  so	  it	  does	  not	  cause	  any	  inflammation	  that	  will	  isolate	  the	  biosensor	  from	  the	  
metabolite	  of	  interest.	  	  
In	  order	  to	  ensure	  that	  our	  biosensor	  has	  the	  desired	  properties,	  certain	  materials	  were	  selected.	  
The	  basis	  of	  the	  biosensor	  is	  a	  glassy	  carbon	  electrode	  (GCE).	  Conductive	  polymers	  were	  used	  to	  create	  a	  
film	  on	  the	  GCE	  surface	  and	  decrease	  the	  biosensor	  response	  time	  by	  aiding	  electrons	  to	  reach	  the	  GCE	  
surface	  more	  rapidly.	  In	  particular,	  polypyrrole	  (PPY)	  was	  chosen	  because	  it	  has	  small	  pores	  which	  
prevent	  interference	  from	  other	  molecules.	  Polyaniline	  (PANI)	  was	  chosen	  for	  its	  high	  conductivity.	  LOX	  
was	  used	  to	  break	  down	  lactate	  to	  create	  the	  electrical	  signal	  for	  the	  biosensor	  to	  measure.	  
Glutaraldehyde	  was	  used	  to	  crosslink	  lactate	  oxidase	  to	  PANI	  to	  prevent	  diffusion	  of	  the	  enzyme	  out	  of	  
the	  polymer	  film.	  The	  final	  design	  consists	  of	  a	  PPY	  layer	  deposited	  onto	  a	  GCE	  followed	  by	  a	  layer	  of	  
PANI	  and	  LOX	  (Fig.	  1).	  
	  













Figure	  1.	  Schematic	  of	  final	  biosensor	  design	  
	  
II.	  METHODS	  
	   Three	  millimeter	  GCE	  were	  polished	  as	  described	  by	  Anglin	  et	  al.	  [5].	  For	  all	  electrochemical	  
experiments,	  the	  GCE	  (working	  electrode)	  was	  used	  with	  an	  Ag/AgCl	  reference	  electrode	  and	  a	  platinum	  
counter	  electrode.	  	  An	  AUTOLAB	  potentiostat	  (Metrohm)	  and	  GPES	  software	  were	  used	  to	  control	  the	  
current	  and	  voltage	  running	  through	  the	  working	  electrode	  and	  to	  record	  data.	  
Biosensor	  Fabrication	  
To	  create	  the	  PPY	  film	  on	  the	  surface	  of	  the	  GCE,	  7	  μL	  of	  pyrrole	  (Sigma-­‐Aldrich)	  was	  added	  to	  10	  mL	  
of	  0.01	  M	  phosphate	  buffered	  saline	  (PBS)	  that	  had	  been	  degassed	  by	  nitrogen	  bubbling	  for	  15	  minutes	  
[6].	  The	  pyrrole	  was	  polymerized	  to	  form	  PPY	  on	  the	  surface	  of	  the	  GCE	  by	  using	  galvanostatic	  
deposition	  at	  a	  current	  of	  25	  mA/cm2	  for	  120	  seconds.	  Then,	  a	  PANI	  film	  was	  created	  on	  top	  of	  the	  PPY	  
film	  by	  polymerizing	  45	  μL	  of	  aniline	  (Sigma-­‐Aldrich)	  in	  degassed	  0.1M	  PBS	  of	  pH	  3.5.	  Nine	  cycles	  of	  
cyclic	  voltammetry	  between	  0.00	  and	  0.95	  V	  were	  used	  to	  polymerize	  the	  aniline.	  5	  μL	  of	  0.1%	  
glutaraldehyde	  (Sigma-­‐Aldrich)	  was	  placed	  on	  top	  of	  the	  polymer	  films	  and	  dried	  at	  room	  temperature	  
for	  30	  minutes.	  5	  μL	  of	  LOX	  (2.9	  mg/mL,	  Sigma-­‐Aldrich)	  was	  added	  on	  top	  of	  the	  PPY-­‐PANI-­‐
glutaraldehyde	  electrode.	  The	  glutaraldehyde	  cross-­‐linked	  the	  LOX	  to	  the	  polymer.	  
Electrochemical	  Experiments	  
For	  each	  test,	  a	  degassed	  solution	  of	  lithium	  lactate	  in	  PBS	  was	  placed	  into	  the	  electrochemical	  cell.	  
To	  measure	  the	  current	  output	  of	  the	  biosensor	  in	  response	  to	  lactate,	  Autolab	  was	  used	  to	  perform	  
amperometry,	  in	  which	  the	  voltage	  is	  held	  constant	  and	  the	  current	  changes	  as	  a	  function	  of	  lactate	  
concentration.	  Cyclic	  voltammetry	  (cycling	  between	  -­‐0.4	  and	  +0.6V	  for	  10	  cycles)	  was	  used	  to	  gauge	  
biosensor	  performance	  as	  a	  function	  of	  lactate	  concentration.	  The	  biosensor’s	  response	  to	  changing	  
lactate	  concentrations	  over	  time	  was	  measured.	  
Cell	  Culture	  
	   Human	  glioblastoma	  cells	  (U87mg,	  ATCC)	  were	  cultured	  in	  Dulbecco’s	  Modified	  Eagle’s	  Medium	  
containing	  10%	  fetal	  bovine	  serum,	  1%	  L-­‐glutamate,	  1%	  penicillin-­‐streptomycin,	  1%	  non-­‐essential	  amino	  
acids,	  for	  48	  hours.	  	  
Biosensor	  Accuracy	  Testing	  
To	  determine	  the	  lactate	  concentration	  secreted	  into	  the	  media	  of	  cultured	  U87MG	  cells,	  ELISA	  was	  
performed	  according	  to	  manufacturer’s	  protocol	  (Sigma	  Aldrich)	  This	  was	  compared	  to	  the	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Analysis	  of	  PPY	  and	  PANI	  Films	  
	   SEM	  images	  of	  the	  PPY	  and	  PPY-­‐PANI	  films	  are	  shown	  in	  Figure	  2.	  The	  PPY	  film	  thickness	  was	  
calculated	  to	  be	  100	  nm.	  	  
Figure	  2.	  SEM	  images	  of	  A)	  PPY	  coating	  and	  B)	  PPY-­‐PANI	  coating	  
Electrochemical	  Testing	  
	   Different	  variations	  and	  combinations	  of	  the	  design	  components	  were	  tested	  iteratively	  in	  order	  to	  
optimize	  the	  biosensor.	  	  Amperometry	  results	  of	  the	  maximum	  current	  detected	  at	  different	  lactate	  
concentrations	  are	  shown	  in	  Figure	  4.	  The	  biosensor	  is	  able	  to	  detect	  the	  decrease	  in	  current	  with	  















Figure	  4.	  Decreasing	  current	  with	  increasing	  lactate	  concentration	  
	  
Increasing	  Lactate	  Levels	  
	   Amperometry	  results	  of	  the	  maximum	  current	  detected	  as	  lactate	  was	  added	  to	  the	  system	  are	  
shown	  in	  Figure	  5.	  The	  biosensor	  is	  able	  to	  detect	  the	  addition	  of	  lactate	  but	  over	  time	  the	  maximum	  
current	  decreases.	  	  

























Figure	  5.	  Current	  response	  with	  increasing	  lactate	  concentration	  
	  
Lactate	  Concentrations	  in	  Cell	  Media	  
	   Media	  collected	  from	  U87mg	  cells	  cultured	  over	  48	  hours	  was	  tested	  with	  an	  ELISA	  and	  the	  
biosensor	  to	  measure	  lactate	  concentration.	  The	  concentration	  of	  lactate	  based	  on	  the	  current	  
measured	  by	  the	  biosensor	  was	  calculated	  by	  using	  a	  standard	  curve	  gathered	  from	  the	  dynamic	  testing.	  
Unfortunately,	  our	  results	  were	  unreasonable.	  
	  
Table	  3:	  The	  average	  current	  read	  by	  the	  biosensor,	  the	  average	  lactate	  concentration	  calculated	  using	  
the	  standard	  curve,	  and	  the	  actual	  lactate	  concentration	  measured	  with	  an	  ELISA	  for	  media	  samples	  






	   Average	  Current	  (A)	   Average	  Lactate	  Concentration	  
Calculated	  (mM)	  
1,000,000	   0.93	  ±	  0.25	   	   2.36E-­‐07	  ±	  5.5E-­‐8	   -­‐46.5	  
500,000	   1.24	  ±	  0.07	   	   2.70E-­‐07	  ±	  4.4E-­‐8	   -­‐55.1	  
100,000	   0.31±	  0.008	   	   1.35E-­‐07±	  3.4E-­‐8	   -­‐21.2	  
	  
V.	  	  DISCUSSION	  
	   The	  PPY-­‐PANI-­‐LOX	  biosensor	  designed	  in	  this	  MQP	  is	  able	  to	  detect	  changes	  in	  lactate	  concentration	  
with	  a	  change	  in	  its	  current	  output.	  However,	  we	  had	  expected	  to	  see	  an	  increase	  in	  current	  as	  lactate	  
concentration	  increased,	  not	  a	  decrease.	  Because	  we	  were	  only	  able	  to	  do	  testing	  once	  on	  properly	  
calibrated	  equipment,	  we	  were	  unable	  to	  explain	  why	  this	  trend	  of	  current	  vs	  concentration	  was	  
negative.	  However,	  the	  biosensor	  was	  shown	  to	  have	  a	  very	  quick	  response	  time	  in	  dynamic	  testing.	  
When	  tested	  with	  cell	  media,	  the	  current	  output	  of	  the	  biosensor	  was	  higher	  than	  during	  testing	  in	  PBS,	  
which	  suggests	  that	  there	  might	  be	  non-­‐specific	  reactions	  from	  other	  molecules	  in	  the	  media	  that	  are	  
leading	  to	  an	  increased	  current	  response.	  
	   Although	  the	  biosensor	  is	  able	  to	  measure	  increased	  current	  with	  increased	  lactate	  concentration,	  
continued	  testing	  and	  validation	  are	  needed.	  Before	  the	  biosensor	  becomes	  an	  implantable	  medical	  
device,	  more	  research	  and	  testing	  must	  be	  completed.	  The	  biosensor	  must	  be	  tested	  over	  a	  period	  of	  
weeks	  and	  months	  at	  physiological	  conditions	  in	  order	  to	  determine	  how	  long	  it	  can	  remain	  effective.	  
Biocompatibility	  tests	  must	  be	  performed	  to	  ensure	  that	  the	  biosensor	  does	  not	  trigger	  an	  inflammatory	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1.  Introduction  
Glioblastoma	  Multiforme	  (GBM)	  is	  an	  extremely	  aggressive	  form	  of	  brain	  cancer,	  with	  a	  three-­‐
year	  survival	  rate	  of	  less	  than	  two	  percent	  (Pelletier	  et	  al.,	  2002).	  Because	  of	  GBM’s	  aggressive	  nature,	  it	  
is	  essential	  to	  find	  an	  effective	  treatment	  and	  be	  able	  to	  closely	  monitor	  the	  progression	  of	  the	  tumor.	  
Current	  monitoring	  methods,	  such	  as	  magnetic	  resonance	  imaging	  (MRI)	  and	  computed	  tomography	  
scans	  (CT	  scans)	  are	  not	  appropriate	  for	  frequent	  use.	  These	  tests	  are	  typically	  performed	  every	  six	  
months,	  during	  which	  time	  a	  GBM	  tumor	  can	  develop	  significantly.	  Additionally,	  these	  imaging	  
modalities	  can	  only	  detect	  large,	  non-­‐diffuse	  tumors.	  A	  small,	  implantable	  biosensor	  could	  allow	  for	  low-­‐
risk	  monitoring	  as	  needed	  of	  the	  progression	  of	  GBM.	  This	  biosensor	  could	  be	  inserted	  minimally	  
invasively	  and	  transmit	  data	  to	  the	  patient	  or	  physician’s	  mobile	  device,	  allowing	  for	  real-­‐time	  
monitoring	  of	  the	  patient’s	  condition.	  Daily	  monitoring	  of	  tumor	  progression	  will	  allow	  a	  medical	  team	  
to	  determine	  the	  efficacy	  of	  a	  particular	  treatment	  on	  a	  patient	  and	  tailor	  the	  patient’s	  treatment	  
accordingly.	  	  
The	  biosensor	  designed	  in	  this	  MQP	  would	  function	  by	  exploiting	  the	  increased	  concentrations	  
of	  lactate	  produced	  by	  GBM	  tumors	  as	  a	  byproduct	  of	  the	  altered	  metabolism	  in	  tumor	  cells.	  We	  
hypothesize	  that	  the	  local	  increase	  in	  lactate	  production	  by	  glioblastoma	  tumor	  cells	  is	  significant	  and	  
detectable	  by	  a	  continuous,	  real-­‐time	  implanted	  biosensor.	  To	  this	  end,	  we	  developed	  a	  lactate	  
biosensor	  based	  on	  lactate	  oxidase,	  an	  enzyme	  that	  catalyzes	  the	  degradation	  of	  lactate	  into	  pyruvate,	  
and	  conductive	  polymers	  (polypyrrole	  and	  polyaniline).	  This	  project	  was	  based	  on	  a	  previous	  Major	  
Qualifying	  Project	  (MQP),	  completed	  in	  May	  2013,	  which	  began	  the	  development	  of	  a	  lactate	  biosensor	  
(Anglin	  et	  al.,	  2013).	  The	  overall	  goal	  of	  the	  current	  project	  was	  to	  design,	  fabricate,	  and	  validate	  a	  film	  
for	  a	  biosensor	  that	  could	  detect	  lactate	  sensitively	  and	  reproducibly,	  with	  a	  short	  response	  time.	  
Desired	  characteristics	  for	  the	  biosensor	  include	  sensitivity,	  selectivity,	  reliability,	  biocompatibility,	  and	  
the	  ability	  to	  remain	  stable	  in	  the	  body	  for	  at	  least	  two	  weeks.	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To	  create	  the	  biosensor,	  we	  created	  design	  alternatives	  utilizing	  different	  conductive	  polymers	  
to	  carry	  the	  charge	  produced	  from	  the	  enzymatic	  degradation	  of	  lactate	  by	  lactate	  oxidase	  to	  the	  
electrode	  surface.	  An	  iterative	  testing	  process	  allowed	  us	  to	  validate	  each	  component	  of	  the	  final	  
design.	  Although	  our	  biosensor	  still	  needs	  further	  testing	  to	  improve	  its	  sensitivity	  and	  specificity,	  we	  
believe	  that	  it	  is	  a	  promising	  start	  to	  an	  implantable	  biosensor	  that	  could	  eventually	  be	  used	  to	  monitor	  
all	  types	  of	  cancer,	  not	  just	  glioblastoma	  multiforme.	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2.  Literature  Review  
2.1  Glioblastoma  Multiforme  
Glioblastoma	  Multiforme	  (GBM)	  is	  one	  of	  the	  most	  common	  forms	  of	  brain	  cancer	  in	  adults,	  
affecting	  3	  out	  of	  100,000	  people	  in	  the	  United	  States	  each	  year	  (Marucci,	  2011).	  These	  malignant	  brain	  
tumors	  are	  classified	  as	  astrocytomas,	  which	  arise	  from	  astrocytes,	  the	  cells	  that	  support	  the	  function	  of	  
neurons.	  (St.	  Jude	  Children’s	  Research	  Hospital,	  2013).	  GBM	  is	  classified	  as	  a	  grade	  IV	  astrocytoma,	  
which	  is	  the	  highest	  and	  most	  serious	  grade.	  Typically,	  high-­‐grade	  astrocytoma	  patients	  receive	  a	  variety	  
of	  treatments	  beginning	  with	  surgery.	  Because	  surgery	  rarely	  removes	  the	  entire	  tumor,	  it	  is	  usually	  
followed	  by	  radiation,	  chemotherapy,	  or	  a	  combination	  of	  the	  two	  (National	  Brain	  Tumor	  Society,	  2013).	  
Generally,	  by	  the	  time	  symptoms	  appear,	  a	  tumor	  has	  spread	  across	  a	  large	  portion	  of	  the	  brain.	  The	  
median	  survival	  time	  after	  diagnosis	  is	  15	  months	  (St.	  Jude	  Children’s	  Research	  Hospital,	  2013),	  with	  
only	  two	  percent	  of	  patients	  surviving	  three	  years	  past	  diagnosis	  (Pelletier	  et	  al.,	  2002).	  There	  are	  two	  
types	  of	  GBM,	  primary	  and	  secondary.	  Primary	  GBM	  is	  more	  common	  and	  aggressive	  than	  secondary	  
GBM,	  which	  can	  arise	  from	  a	  lower	  grade	  astrocytoma	  (Reardon	  et	  al.,	  2006).	  GBM	  is	  more	  common	  in	  
adults	  than	  children	  and	  more	  common	  in	  men	  than	  women	  (St.	  Jude	  Children’s	  Research	  Hospital,	  
2013).	  
2.1.1  Symptoms  
Both	  forms	  of	  GBM	  display	  similar	  symptoms.	  Symptoms	  can	  vary	  between	  patients	  and	  depend	  
on	  where	  the	  tumor	  is	  located	  in	  the	  brain.	  The	  most	  common	  symptoms	  that	  patients	  exhibit	  are	  a	  
result	  of	  increased	  pressure	  in	  the	  brain	  and	  can	  include	  headache,	  nausea,	  vomiting,	  and	  drowsiness.	  
Headaches	  are	  usually	  the	  first	  symptom	  and	  often	  increase	  in	  frequency	  as	  the	  tumor	  grows.	  Other	  
common	  symptoms	  include	  seizures,	  body	  weakness,	  memory	  loss,	  speech	  difficulties	  and	  vision	  
changes,	  such	  as	  blurred	  or	  double	  vision	  (American	  Brain	  Tumor	  Association,	  2013).	  Some	  patients	  also	  
exhibit	  changes	  in	  mood,	  mental	  function,	  or	  personality.	  	  




GBM	  is	  an	  extremely	  difficult	  form	  of	  cancer	  to	  treat	  due	  to	  its	  rapid	  progression	  and	  the	  
proximity	  of	  tumors	  to	  important	  areas	  of	  the	  brain,	  which	  makes	  surgery	  difficult.	  There	  are	  a	  variety	  of	  
treatments	  available	  for	  GBM,	  with	  many	  more	  treatments	  currently	  in	  development.	  	  	  
Generally,	  the	  first	  step	  in	  the	  treatment	  process	  for	  GBM	  is	  surgery	  to	  collect	  a	  biopsy	  and	  
remove	  as	  much	  of	  the	  tumor	  as	  possible.	  The	  biopsy	  is	  used	  to	  confirm	  the	  diagnosis.	  Physicians	  can	  
also	  examine	  these	  tissue	  samples	  and	  gather	  information	  that	  can	  aid	  in	  creating	  an	  effective	  treatment	  
plan.	  Often,	  it	  is	  impossible	  to	  remove	  the	  tumor	  entirely	  because	  it	  is	  able	  to	  easily	  maneuver	  into	  the	  
crevasses	  in	  the	  brain.	  Tumor	  re-­‐sectioning	  is	  when	  abnormal	  tissue	  is	  surgically	  removed.	  Removing	  this	  
abnormal	  tissue	  has	  many	  benefits	  including	  reduced	  symptoms,	  improving	  function	  and	  decreasing	  
pressure	  within	  the	  skull.	  These	  benefits	  help	  to	  improve	  the	  quality	  and	  length	  of	  life	  for	  patients.	  There	  
are	  also	  risks	  involved	  in	  re-­‐sectioning	  and	  it	  is	  more	  difficult	  when	  the	  tumor	  grows	  near	  parts	  of	  the	  
brain	  that	  control	  important	  functions	  such	  as	  speech	  and	  motor	  ability.	  During	  re-­‐sectioning,	  nerves	  
and	  blood	  vessels	  that	  control	  vital	  functions	  can	  be	  damaged	  and	  cause	  loss	  of	  sensation,	  sight,	  
memory,	  movement	  and	  other	  functions.	  Other	  serious	  risks	  include	  infection,	  seizures,	  coma	  and	  even	  
death	  (American	  Brain	  Tumor	  Association,	  2013).	  	  
Radiotherapy,	  also	  known	  as	  radiation	  therapy	  or	  simply	  radiation,	  is	  when	  high-­‐energy	  rays,	  
such	  as	  x-­‐rays,	  are	  used	  to	  destroy	  diseased	  tissue.	  Radiation	  can	  also	  damage	  healthy	  tissue.	  The	  
healthy	  tissue	  is	  often	  able	  to	  repair	  itself,	  whereas	  the	  diseased	  tissue	  cannot.	  It	  is	  often	  used	  in	  
conjunction	  with	  surgery	  and	  chemotherapy,	  and	  has	  been	  shown	  to	  increase	  the	  survival	  time	  after	  
diagnosis	  by	  4-­‐12	  months	  in	  elderly	  patients	  (Bruce,	  2013).	  Radiation	  is	  most	  often	  chosen	  as	  the	  initial	  
postoperative	  treatment	  for	  GBM.	  Responsiveness	  to	  radiotherapy	  varies,	  but	  in	  most	  cases	  the	  tumor	  
size	  is	  reduced	  dramatically.	  Radiotherapy	  can	  induce	  remission,	  although	  it	  is	  often	  brief.	  Tumors	  
typically	  reappear	  within	  two	  centimeters	  of	  the	  original	  tumor	  site	  and	  increase	  in	  size	  within	  one	  year	  
after	  radiotherapy	  (Bruce,	  2013).	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For	  many	  patients	  with	  GBM,	  chemotherapy	  is	  part	  of	  their	  treatment	  regimen.	  Studies	  have	  
shown	  that	  chemotherapy	  is	  beneficial	  for	  over	  25%	  of	  patients	  who	  receive	  it.	  For	  example,	  6-­‐10%	  of	  
patients	  have	  an	  increased	  survival	  time	  after	  chemotherapy	  (Bruce,	  2013).	  The	  most	  popular	  
chemotherapy	  drug	  is	  temozolomide,	  an	  oral	  drug	  used	  in	  the	  treatment	  of	  GBM.	  Other	  forms	  of	  
chemotherapy	  include	  implanting	  biodegradable	  polymer	  wafers	  that	  release	  carmustine	  (Gliadel).	  
Controlled	  release	  systems	  are	  also	  being	  developed	  for	  other	  chemotherapy	  drugs	  including	  
doxorubicin	  and	  paclitaxel	  (Ong	  et	  al.,	  2009).	  	  
2.1.3  Monitoring  GBM  Progression  
There	  are	  various	  methods	  to	  monitor	  the	  progression	  of	  cancer	  including	  Magnetic	  Resonance	  
Imaging	  (MRI),	  Computed	  Tomography	  Scans	  (CT	  Scans)	  and	  Magnetic	  Resonance	  Spectroscopy	  (MRS).	  
These	  procedures	  can	  sometimes	  be	  ineffective	  at	  detecting	  the	  tumors	  and	  can	  cause	  detrimental	  
effects	  to	  the	  patient’s	  health.	  Due	  to	  these	  adverse	  effects,	  a	  more	  effective	  and	  less	  harmful	  method	  
to	  assessing	  the	  progression	  of	  GBM	  is	  needed.	  	  
Magnetic	  Resonance	  Imaging	  (MRI)	  is	  considered	  the	  gold	  standard	  of	  neuroimaging	  and	  is	  able	  
to	  determine	  the	  size	  and	  location	  of	  the	  tumor.	  An	  MRI	  uses	  magnetic	  fields	  and	  radio	  waves	  to	  take	  
images	  primarily	  of	  soft	  tissues	  inside	  of	  the	  body	  (MRI	  Scan,	  2013).	  This	  form	  of	  imaging	  is	  effective	  at	  
recording	  images	  of	  soft	  tissue.	  Although	  this	  technology	  is	  beneficial	  in	  monitoring	  the	  location	  and	  size	  
of	  a	  tumor,	  it	  cannot	  be	  used	  to	  diagnose	  GBM	  (Armstrong,	  2009).	  A	  biopsy	  can	  be	  performed	  once	  the	  
location	  of	  a	  suspected	  tumor	  is	  pinpointed	  using	  an	  MRI.	  	  
Computed	  Tomography	  (CT)	  scans	  use	  X-­‐rays	  and	  digital	  computing	  technology	  to	  create	  two-­‐	  
and	  three-­‐dimensional	  images	  of	  the	  brain.	  These	  scans	  can	  create	  an	  image	  of	  every	  tissue	  type,	  
including	  bone,	  blood	  vessels,	  soft	  tissue,	  and	  cancerous	  tissue.	  While	  CT	  scans	  can	  be	  very	  beneficial,	  
they	  require	  a	  dye	  or	  contrast	  agent	  to	  be	  injected	  into	  patients	  to	  enhance	  the	  image	  and	  expose	  
patients	  to	  radiation	  (Roberts,	  H.	  et	  al.,	  2002).	  CT	  scans	  can	  also	  be	  ineffective	  in	  detecting	  small	  tumors.	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Magnetic	  Resonance	  Spectroscopy	  (MRS)	  is	  a	  developing	  technology	  that	  can	  be	  used	  to	  
determine	  biochemical	  changes	  in	  tissue	  or	  fluid	  samples.	  MRS	  can	  detect	  the	  concentration	  of	  
metabolites	  in	  the	  tissue,	  which	  can	  make	  a	  cancerous	  area	  apparent	  when	  compared	  to	  the	  healthy	  
brain.	  MRS	  can	  also	  be	  used	  to	  monitor	  a	  tumor	  site	  and	  differentiate	  between	  recurring	  tumor	  tissue	  
and	  damage	  from	  radiotherapy	  treatments	  (Brandes,	  2008).	  MRS	  has	  some	  limitations,	  most	  notably	  
inaccuracy	  when	  performed	  in	  or	  near	  certain	  tissues,	  such	  as	  bone	  or	  fat,	  air,	  or	  hemorrhages.	  This	  is	  
especially	  true	  in	  areas	  of	  the	  brain	  near	  the	  sinus	  pathways,	  calvarial	  bone,	  and	  skull	  base	  (Gujar	  et	  al.,	  
2005).	  	  
2.2  Cellular  Metabolism    
Cellular	  metabolism	  in	  GBM	  is	  inherently	  different	  from	  the	  metabolism	  of	  healthy	  brain	  tissue	  
(Marie	  and	  Shinjo,	  2011,	  Vander	  Heiden	  et	  al.,	  2009,	  Wolf	  et	  al.,	  2010),	  as	  we	  will	  discuss	  further	  in	  the	  
sections	  below.	  Our	  biosensor	  will	  exploit	  these	  differences	  to	  identify	  the	  presence	  of	  a	  tumor	  and	  
quantify	  the	  progression	  of	  GBM.	  
2.2.1  Non-­‐cancerous  Cel ls      
Cells	  break	  down	  carbohydrates,	  lipids,	  and	  proteins	  in	  order	  to	  produce	  energy	  by	  a	  variety	  of	  
chemical	  processes,	  collectively	  known	  as	  cellular	  metabolism.	  In	  healthy,	  non-­‐proliferative	  tissue,	  
intracellular	  glucose	  undergoes	  glycolysis	  to	  form	  pyruvate.	  If	  oxygen	  is	  present	  in	  sufficient	  quantities,	  
the	  pyruvate	  enters	  the	  mitochondria,	  undergoes	  the	  tricarboxylic	  acid	  (TCA)	  cycle,	  and	  causes	  the	  
production	  of	  36	  molecules	  of	  adenosine	  triphosphate	  (ATP)	  per	  molecule	  of	  glucose	  by	  the	  process	  of	  
oxidative	  phosphorylation.	  In	  the	  absence	  of	  oxygen,	  such	  as	  in	  times	  of	  heavy	  exercise,	  the	  pyruvate	  is	  
broken	  down	  to	  lactate	  and	  produces	  two	  molecules	  of	  ATP,	  in	  a	  process	  known	  as	  anaerobic	  glycolysis	  
(Marie	  and	  Shinjo,	  2011).	  	  
2.2.2  Warburg  Effect      
Cancerous	  cells,	  including	  those	  of	  GBM,	  do	  not	  follow	  typical	  cellular	  metabolism.	  Figure	  1	  
compares	  the	  metabolism	  of	  healthy	  cells	  to	  that	  of	  cancerous	  tissue.	  	  




Figure	  1:	  Glucose	  Metabolism	  Diagram	  
Glucose	  metabolism	  of	  healthy	  differentiated	  tissue	  compared	  to	  tumor	  and	  proliferative	  tissue	  (Vander	  Heiden	  
et	  al.,	  2009).	  
	  
In	  cancer	  cells,	  pyruvate	  is	  broken	  down	  into	  lactate	  to	  generate	  four	  molecules	  of	  ATP,	  even	  if	  
oxygen	  is	  present.	  This	  is	  known	  as	  aerobic	  glycolysis,	  and	  was	  first	  noted	  by	  Otto	  Warburg	  in	  1924.	  The	  
difference	  in	  cellular	  metabolism	  in	  cancerous	  cells	  is	  therefore	  named	  the	  “Warburg	  Effect”	  (Vander	  
Heiden	  et	  al.,	  2009,	  Marie	  and	  Shinjo,	  2011,	  Wolf	  et	  al.,	  2010).	  The	  Warburg	  Effect	  extends	  to	  other	  
aspects	  of	  metabolism	  besides	  glucose,	  resulting	  in	  the	  production	  of	  more	  lipids,	  amino	  acids,	  and	  
nucleotides.	  Aerobic	  glycolysis	  is	  energetically	  inefficient	  –	  one	  molecule	  of	  glucose	  only	  produces	  four	  
molecules	  of	  ATP,	  instead	  of	  the	  36	  molecules	  produced	  in	  oxidative	  phosphorylation.	  	  However,	  this	  
altered	  metabolism	  has	  many	  benefits	  for	  the	  survival	  of	  the	  cancer.	  The	  shift	  from	  energy	  production	  to	  
the	  production	  of	  lipids	  and	  nucleotides	  allows	  the	  cell	  to	  quickly	  create	  all	  of	  the	  materials	  necessary	  
for	  it	  to	  duplicate.	  This	  enables	  the	  fast	  proliferation	  of	  the	  cancerous	  cells	  (Vander	  Heiden	  et	  al.,	  2009).	  
The	  increase	  in	  lactate	  production	  creates	  an	  acidic	  environment	  surrounding	  the	  tumor,	  which	  
encourages	  tumor	  cell	  invasion	  (Marie	  and	  Shinjo,	  2011).	  Glutaminolysis,	  a	  process	  in	  which	  glutamine	  is	  
broken	  down	  into	  glutamate	  and	  ammonia,	  is	  dramatically	  increased	  in	  cancer	  cells.	  This	  process	  
provides	  a	  nitrogen	  source	  for	  the	  cell,	  allowing	  it	  to	  create	  amino	  acids	  and	  nucleotides	  (Dang,	  2010).	  
The	  altered	  metabolism	  in	  cancer	  cells	  results	  in	  increased	  levels	  of	  lactate,	  alanine,	  glutamate,	  and	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amino	  acids,	  but	  a	  decreased	  level	  of	  glucose	  (Vander	  Heiden	  et	  al.,	  2009).	  Therefore,	  by	  monitoring	  
metabolite	  concentration,	  cancer	  progression	  can	  be	  monitored.	  	  
2.3  Metabolites  found  in  Glioblastoma  Multiforme  Cells   
Elevated	  levels	  of	  certain	  metabolites	  due	  to	  the	  Warburg	  Effect	  could	  help	  with	  determining	  
the	  progression	  of	  brain	  cancers	  such	  as	  GBM.	  Lactate	  is	  one	  of	  several	  metabolites	  that	  have	  
statistically	  significant	  changes	  in	  concentrations	  in	  GBM	  cells	  compared	  to	  normal	  brain	  cells	  (Roslin	  et	  
al.,	  2003).	  An	  increase	  in	  lactate	  concentration	  is	  a	  common	  feature	  of	  cancer	  cells.	  The	  average	  normal	  
plasma	  lactate	  concentration	  ranges	  from	  0.3-­‐1.3	  mM	  for	  healthy	  adults,	  during	  heavy	  exercise,	  these	  
levels	  increase	  above	  5	  mM	  (Phypers,	  B.	  and	  Pierce,	  J.	  2006).	  Lactate	  levels	  above	  20	  mM	  have	  been	  
observed	  in	  GBM	  patients	  (Cheng,	  L.	  et	  al.,	  2000).	  Lactate	  is	  an	  important	  metabolite	  to	  be	  studied	  due	  
to	  the	  capability	  of	  lactate	  to	  predict	  the	  survival	  period	  of	  patients.	  Lactate	  concentrations	  have	  been	  
shown	  to	  be	  inversely	  correlated	  to	  patient	  survival.	  Increased	  lactate	  concentrations	  have	  also	  been	  
shown	  to	  have	  a	  positive	  correlation	  with	  the	  increase	  in	  resistance	  to	  radiotherapy	  in	  tumor	  cells.	  
Lactate	  concentrations	  generally	  decrease	  in	  animals	  after	  both	  chemotherapy	  and	  radiotherapy.	  
Monitoring	  of	  lactate	  concentrations	  is	  a	  good	  determinant	  for	  the	  progression	  of	  cancer	  because	  
lactate	  concentration	  is	  proportional	  to	  tumor	  size	  (Hirschhaeuser	  et.	  al,	  2011).	  	  
2.4  Biosensors  
A	  biosensor	  is	  a	  device	  made	  of	  a	  biological	  component	  (enzymes,	  cells,	  DNA)	  and	  a	  physical	  
transducer	  that	  converts	  the	  concentration	  of	  a	  biological	  analyte	  into	  an	  electrical	  signal	  (Keusgen,	  
2002).	  This	  biological	  analyte	  can	  be	  in	  the	  form	  of	  proteins,	  metabolites,	  drugs,	  or	  other	  biological	  
chemicals.	  Many	  biosensors	  are	  enzymatic.	  An	  enzyme	  on	  the	  biosensor	  surface	  causes	  the	  analyte	  of	  
interest	  to	  break	  down	  in	  such	  a	  way	  that	  a	  physico-­‐chemical	  signal	  is	  produced.	  This	  is	  converted	  by	  the	  
transducer	  into	  an	  electrical	  signal,	  which	  is	  then	  interpreted	  by	  a	  computer.	  The	  electrical	  signal	  read	  by	  
the	  computer	  is	  directly	  proportional	  to	  the	  amount	  of	  analyte	  present	  (Sassolas	  et	  al,	  2012).	  Figure	  2	  





Figure	  2:	  Scheme	  of	  a	  Biosensor	  
Diagram	  of	  how	  biosensors	  work	  (Sassolas	  et	  al,	  2012).	  
	  
2.4.1  History  of   Biosensors  
The	  first	  biosensor	  was	  created	  by	  Clark	  and	  Lyons	  in	  1962	  at	  the	  Cincinnati	  Children’s	  Hospital	  
(Anglin	  et	  al.,	  2013,	  Wang,	  2008,	  Keusgen,	  2002,	  Wilson	  and	  Gifford,	  2005).	  This	  biosensor	  detected	  
glucose	  by	  using	  glucose	  oxidase	  to	  break	  down	  glucose	  into	  hydrogen	  peroxide,	  which	  subsequently	  
broke	  down	  into	  oxygen	  and	  electrons.	  The	  electrons	  created	  an	  electrical	  signal	  that	  could	  be	  
quantified.	  This	  allowed	  doctors	  to	  monitor	  the	  blood	  sugar	  levels	  of	  patients	  for	  the	  first	  time	  (Wang,	  
2008,	  Ronkainen	  et	  al.,	  2010).	  The	  main	  challenge	  faced	  by	  early	  biosensors	  is	  the	  poor	  aqueous	  
solubility	  of	  oxygen,	  which	  was	  needed	  as	  a	  cofactor	  to	  make	  the	  enzyme	  work	  effectively.	  The	  second	  
generation	  of	  biosensors	  used	  mediators	  to	  shuttle	  electrons	  from	  the	  redox	  site	  of	  the	  enzyme	  to	  the	  
surface	  of	  the	  electrode,	  replacing	  the	  function	  of	  oxygen.	  Examples	  of	  mediators	  include	  ferrocene	  
derivatives,	  conducting	  organic	  salts,	  and	  transition	  metal	  complexes.	  Commercially	  available	  glucose	  
biosensors	  used	  in	  the	  monitoring	  of	  diabetes	  mellitus	  use	  this	  second	  generation	  technology	  (Wang,	  
2008).	  The	  field	  of	  biosensors	  is	  now	  moving	  into	  the	  third	  generation,	  in	  which	  mediators	  will	  be	  
eliminated	  and	  biosensors	  will	  be	  designed	  so	  that	  there	  is	  direct	  electron	  transfer	  between	  the	  redox	  
site	  of	  the	  enzyme	  and	  the	  surface	  of	  the	  electrode	  (Wang,	  2008).	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Biosensors	  allow	  for	  frequent	  monitoring	  of	  the	  concentrations	  of	  biomolecules	  in	  applications	  
such	  as	  diagnostic	  testing,	  development	  of	  new	  pharmaceuticals,	  and	  monitoring	  of	  patients	  in	  a	  clinical	  
setting.	  Glucose	  biosensors,	  perhaps	  the	  best-­‐known	  example	  of	  a	  biosensor,	  are	  used	  multiple	  times	  a	  
day	  by	  patients	  with	  diabetes	  mellitus	  in	  order	  to	  track	  blood	  sugar	  (Wang,	  2008).	  In	  the	  future,	  as	  more	  
is	  understood	  about	  diseases	  and	  as	  biosensor	  technology	  develops,	  a	  biosensor	  could	  be	  implanted	  to	  
detect	  the	  concentrations	  of	  multiple	  metabolites	  or	  analytes	  and	  inform	  medical	  personnel	  of	  changes	  
in	  a	  patient’s	  condition.	  This	  project	  aims	  to	  detect	  the	  concentration	  of	  lactate	  and	  glutamate	  in	  order	  
to	  monitor	  tumor	  size	  and	  progression	  in	  GBM	  patients.	  
2.4.2  Biosensor  Fai lure  
There	  are	  several	  factors	  that	  can	  cause	  biosensor	  failure.	  The	  most	  important	  challenge	  to	  
overcome	  when	  designing	  a	  biosensor	  is	  to	  make	  it	  compatible	  in	  vivo.	  	  When	  foreign	  materials	  such	  as	  
implantable	  biosensors	  enter	  the	  body,	  they	  activate	  the	  foreign	  body	  response	  (Wang,	  2008,	  Kotanen	  
et	  al.,	  2012,	  Wilson	  and	  Gifford,	  2005,	  Bannish	  et	  al.,	  2013).	  The	  immune	  response	  becomes	  activated,	  
leading	  to	  inflammation	  and	  the	  activation	  of	  macrophages.	  These	  macrophages	  release	  cytokines	  that	  
recruit	  more	  macrophages	  to	  the	  implantation	  site.	  Within	  two	  to	  three	  weeks,	  these	  macrophages	  form	  
a	  fibrous	  encapsulation	  of	  the	  biosensor,	  leading	  to	  loss	  of	  function.	  This	  process	  is	  known	  as	  bio-­‐fouling	  
(Bannish	  et	  al.,	  2013,	  Kotanen	  et	  al.,	  2012,	  Wisniewski	  and	  Reichert,	  2000)	  and	  can	  be	  seen	  more	  clearly	  
in	  Figure	  3.	  Titanium	  oxide	  may	  be	  used	  in	  conjunction	  with	  anti-­‐inflammatory	  drugs	  to	  slow	  this	  process	  
and	  increase	  biocompatibility	  (Bannish	  et	  al.,	  2013).	  Biosensors	  that	  use	  enzymes	  may	  fail	  due	  to	  
enzyme	  unfolding	  in	  an	  unfavorable	  chemical	  environment	  or	  	  enzymatic	  degradation	  caused	  by	  
proteases	  released	  by	  neighboring	  cells.	  Failure	  of	  the	  biosensor’s	  materials	  can	  be	  due	  to	  mechanical	  
stresses	  or	  time	  and	  temperature	  related	  changes	  of	  the	  membrane	  covering	  the	  electrode	  surface	  
(Kotanen	  et	  al.,	  2012).	  	  




Figure	  3:	  Fibrous	  Encapsulation	  of	  a	  Biosensor	  
Fibrous	  encapsulation	  of	  a	  biosensor	  due	  to	  bio-­‐fouling	  (Wisniewski	  and	  Reichert,	  2000).	  
	  
2.4.3  Desired  Qual it ies   of   a   Biosensor  
There	  are	  many	  qualities	  desired	  when	  designing	  a	  biosensor.	  The	  biosensor	  must	  be	  sensitive	  
enough	  to	  detect	  small	  changes	  in	  analyte	  concentration	  and	  be	  capable	  of	  detecting	  analyte	  
concentrations	  within	  the	  physiological	  range.	  A	  biosensor	  should	  be	  selective,	  in	  that	  it	  measures	  the	  
analyte	  of	  interest	  without	  any	  interference	  from	  other	  molecules.	  It	  must	  be	  stable	  in	  appropriate	  
conditions	  for	  extended	  periods	  of	  time	  and	  not	  undergo	  degradation	  within	  the	  body.	  Finally,	  a	  
biosensor	  must	  be	  biocompatible	  and	  not	  induce	  the	  foreign	  body	  response	  (Anglin	  et	  al.,	  2013).	  
2.4.4  Sensors  for   GBM  
Some	  biosensors	  have	  been	  developed	  for	  use	  in	  GBM,	  although	  none	  have	  achieved	  clinical	  
use.	  Interestingly,	  they	  all	  approach	  the	  problem	  of	  monitoring	  the	  progression	  of	  GBM	  in	  different	  
ways.	  Hirata	  et	  al.	  (2012)	  have	  developed	  a	  biosensor	  that	  employs	  genetically	  altered	  genes	  that	  
promote	  tumor	  invasion	  and	  express	  green	  fluorescent	  protein.	  By	  using	  Fluorescent	  Resonance	  Energy	  
Transfer	  (FRET)	  imaging,	  they	  can	  monitor	  the	  invasion	  of	  GBM	  into	  surrounding	  tissue.	  In	  2013,	  Zadran	  
et	  al.	  created	  a	  GBM	  biosensor	  to	  detect	  ATP	  in	  GBM	  cell	  lines.	  This	  was	  also	  based	  on	  fluorescence,	  but	  
instead	  of	  FRET,	  Enhanced	  Acceptor	  Fluorescence	  (EAF)	  was	  used.	  This	  is	  a	  process	  in	  which	  fluorescent	  
proteins	  are	  only	  activated	  when	  they	  bind	  to	  ATP.	  Baraket	  et	  al.	  (2010)	  used	  a	  formaldehyde	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dehydrogenase	  enzyme	  coupled	  with	  carbon	  nanotubes	  to	  monitor	  the	  release	  of	  formaldehyde	  by	  
GBM	  cells	  being	  treated	  with	  a	  formaldehyde-­‐based	  anti-­‐cancer	  drug.	  Castillo	  et	  al.	  (2005)	  developed	  a	  
biosensor	  to	  detect	  levels	  of	  glutamate	  and	  nitric	  oxide	  in	  C6-­‐glioma	  cells,	  but	  only	  implemented	  this	  
technology	  on	  in	  vitro	  drug	  screening	  systems.	  Most	  recently,	  a	  previous	  Major	  Qualifying	  Project	  team	  
developed	  a	  biosensor	  to	  detect	  the	  concentration	  of	  lactate	  produced	  by	  GBM	  cells.	  This	  biosensor	  was	  
based	  on	  lactate	  oxidase	  and	  polypyrrole	  (Anglin	  et	  al.,	  2013).	  This	  project	  continues	  in	  their	  footsteps	  
by	  redesigning	  a	  lactate	  biosensor	  for	  better	  performance.	  	  
2.4.5  Materia ls   Used   in   Biosensors  
A	  variety	  of	  biomaterials	  can	  be	  used	  in	  the	  fabrication	  of	  biosensors	  in	  order	  to	  optimize	  
function	  and	  prevent	  adverse	  effects.	  Enzymatic	  biosensors	  are	  typically	  composed	  of	  an	  electrode,	  an	  
enzyme,	  and	  a	  conductive	  entity	  that	  speeds	  the	  transfer	  of	  electrons	  from	  the	  enzyme	  redox	  site	  to	  the	  
electrode	  surface.	  Immunosensors	  are	  similar	  to	  enzymatic	  biosensors	  but	  use	  antibodies	  as	  their	  
sensing	  element.	  Other	  types	  of	  biosensors	  include	  microbe-­‐based	  biosensors	  and	  potentiometric	  
biosensors.	  Different	  materials	  may	  be	  used	  for	  the	  purpose	  of	  improving	  the	  biocompatibility	  or	  other	  
properties	  of	  the	  biosensor.	  In	  this	  section,	  we	  will	  review	  some	  of	  the	  materials	  commonly	  used	  in	  
biosensors.	  	  
2.4.5.1  Electrode  Material  
There	  are	  many	  different	  options	  for	  electrode	  material	  including	  glassy	  carbon,	  gold,	  platinum	  
and	  palladium.	  Platinum	  has	  the	  shortest	  response	  time,	  most	  efficiently	  breaking	  down	  hydrogen	  
peroxide	  into	  electrons,	  but	  can	  be	  mechanically	  unstable	  when	  electrochemical	  layers	  are	  deposited	  
onto	  it.	  Palladium	  is	  more	  stable	  for	  electrochemical	  deposition	  (O’Neill,	  R.,	  et	  al.,	  2004).	  Gold	  electrodes	  
are	  unstable	  at	  potentials	  above	  700	  mV	  (O’Neill,	  R.,	  et	  al.,	  2004).	  Glassy	  carbon	  (GC)	  electrodes	  are	  
used	  very	  commonly	  in	  biosensors	  because	  of	  their	  low	  cost	  and	  sufficient	  mechanical	  and	  electrical	  
properties	  (De	  Benedetto,	  G.E.,	  et	  al.,	  1996).	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2.4.5.2  Carbon  nanotubes  
Carbon	  nanotubes	  (CNTs)	  are	  single-­‐walled	  or	  multi-­‐walled	  hollow	  structures	  composed	  entirely	  
of	  carbon.	  They	  have	  many	  interesting	  properties,	  including	  an	  extremely	  high	  elastic	  modulus,	  good	  
surface	  area	  to	  volume	  ratio,	  a	  hollow	  core	  that	  can	  store	  other	  molecules,	  simple	  fabrication,	  and	  
metallic	  and	  semiconducting	  electron	  transport.	  CNTs	  can	  also	  be	  functionalized	  for	  further	  
biocompatibility	  or	  other	  properties.	  It	  has	  been	  found	  that	  CNTs	  enhance	  the	  electrochemical	  activity	  
of	  biomolecules	  and	  improve	  the	  electron-­‐transfer	  reaction	  in	  proteins	  (Wang,	  2005,	  Balasubramanian	  
and	  Burghard,	  2006).	  These	  properties	  have	  led	  to	  an	  interest	  in	  using	  CNTs	  for	  a	  variety	  of	  novel	  
technologies,	  including	  electrochemical	  actuators,	  batteries,	  tips	  for	  scanning	  probe	  microscopy,	  and	  
sensors	  (Sotiropoulou	  and	  Chaniotakis,	  2003).	  CNTs	  have	  been	  used	  in	  biosensors	  to	  facilitate	  the	  
transfer	  of	  electrons	  between	  the	  enzyme	  redox	  site	  and	  the	  surface	  of	  the	  electrode.	  The	  addition	  of	  
CNTs	  can	  increase	  the	  sensitivity	  of	  the	  biosensor.	  In	  particular,	  CNTs	  are	  particularly	  attractive	  for	  
dehydrogenase	  and	  oxidase	  based	  biosensors	  (Wang,	  2005).	  The	  CNTs	  can	  form	  part	  of	  the	  electrode	  
itself,	  form	  a	  direct	  attachment	  with	  the	  enzyme,	  or	  be	  incorporated	  as	  part	  of	  an	  electroconductive	  
polymer	  film	  such	  as	  polyaniline	  or	  polypyrrole	  (Wang,	  2005,	  Balasubramanian	  and	  Burghard,	  2006).	  
CNT	  based	  biosensors	  have	  been	  used	  for	  a	  variety	  of	  analytes,	  including	  glucose,	  dopamine,	  and	  
glycerol.	  (Balasubramanian	  and	  Burghard,	  2006).	  	  
2.4.6  Enzyme  Entrapment  on  Biosensor   
There	  are	  a	  variety	  of	  different	  ways	  that	  enzymes	  can	  be	  immobilized	  on	  the	  surface	  of	  a	  
biosensor.	  Each	  method	  has	  different	  advantages	  and	  disadvantages.	  The	  main	  methods	  of	  enzyme	  
immobilization	  are	  described	  below.	  	  
2.4.6.1  Adsorption  
Physical	  adsorption	  is	  when	  the	  enzyme	  is	  attached	  directly	  to	  the	  electrode.	  The	  electrode	  is	  
brought	  into	  contact	  with	  the	  enzyme	  dissolved	  in	  solution,	  which	  forms	  weak	  bonds	  between	  the	  
enzyme	  and	  the	  electrode	  surface.	  Excess	  enzyme	  is	  then	  washed	  off.	  Although	  this	  method	  is	  simple	  
	   	   Project	  BME-­‐AJ1-­‐SZ1	  
27	  
	  
and	  does	  not	  denature	  the	  proteins,	  the	  weak	  bonds	  make	  it	  easy	  for	  the	  enzyme	  to	  detach	  from	  the	  
electrode,	  decreasing	  the	  stability	  (Sassolas	  et	  al.,	  2012).	  
2.4.6.2  Entrapment  
In	  the	  entrapment	  method,	  enzymes	  are	  trapped	  within	  a	  polymer	  or	  gel	  scaffold	  and	  deposited	  
onto	  the	  electrode	  surface.	  Immobilizing	  enzymes	  within	  the	  polymer	  or	  gel	  matrix	  is	  simple	  and	  
multiple	  enzymes,	  mediators	  and	  other	  additives	  can	  all	  be	  entrapped	  at	  once.	  The	  size	  of	  the	  pores	  in	  
the	  scaffold	  has	  a	  significant	  effect	  on	  the	  sensitivity	  of	  the	  biosensor.	  If	  the	  pores	  are	  too	  small,	  the	  
metabolite	  of	  interest	  cannot	  reach	  the	  enzyme	  and	  the	  biosensor	  will	  be	  unable	  to	  measure	  the	  
metabolite	  level.	  If	  the	  pores	  are	  too	  large,	  it	  can	  decrease	  the	  selectivity	  of	  the	  biosensor,	  allowing	  
multiples	  metabolites	  to	  reach	  the	  enzyme	  and	  electrode.	  A	  drawback	  of	  using	  this	  method	  is	  that	  the	  
enzyme	  can	  diffuse	  out	  of	  the	  scaffold,	  rendering	  the	  biosensor	  useless	  (Sassolas	  et	  al.,	  2012).	  
2.4.6.3  Crosslinking  
In	  the	  crosslinking	  method,	  enzymes	  are	  bonded	  with	  itself	  or	  inert	  molecules.	  This	  is	  a	  simple	  
process	  and	  forms	  strong	  bonds	  between	  molecules.	  This	  method	  has	  been	  used	  in	  a	  variety	  of	  
biosensors	  including	  detecting	  blood	  glucose	  levels	  (Pei	  et	  al.,	  2004)	  and	  cholesterol	  (Basu	  et	  al.	  2007).	  
The	  main	  drawback	  of	  using	  this	  form	  of	  enzyme	  immobilization	  is	  the	  loss	  of	  activity	  due	  to	  distortion	  
or	  chemical	  alterations	  due	  to	  the	  bonds	  created	  in	  the	  crosslinking	  process	  (Sassolas	  et	  al.,	  2012).	  
Glutaraldehyde	  is	  a	  cross	  linker	  that	  is	  commonly	  used	  to	  immobilize	  a	  variety	  of	  enzymes	  including	  
lactate	  oxidase	  and	  glucose	  oxidase	  (Moser	  et	  al.,	  2002).	  For	  example,	  lactate	  oxidase	  can	  be	  
immobilized	  via	  glutaraldehyde	  crosslinking	  onto	  a	  polypyrrole-­‐coated	  electrode.	  One	  end	  of	  the	  
glutaraldehyde	  molecule	  binds	  to	  the	  amine	  groups	  of	  the	  polypyrrole	  film.	  The	  other	  end	  of	  
glutaraldehyde	  binds	  to	  amine	  groups	  of	  lysine	  and	  arginine	  residues	  within	  the	  lactate	  oxidase	  
molecule.	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2.5  Electroconductive  Polymers  
Electroconductive	  polymers	  are	  able	  to	  conduct	  an	  electric	  charge	  due	  to	  the	  presence	  of	  one	  
unpaired	  electron	  per	  atom	  in	  the	  carbon	  backbone	  of	  the	  structure.	  This	  allows	  electrons	  to	  travel	  
through	  the	  polymer	  with	  little	  resistance.	  An	  important	  application	  of	  electroconductive	  polymers	  is	  in	  
biosensors.	  Electroconductive	  polymers	  can	  transfer	  electrical	  charge	  from	  the	  enzyme	  to	  the	  surface	  of	  
the	  electrode.	  This	  increases	  the	  sensitivity	  and	  decreases	  the	  response	  time	  of	  the	  biosensor	  (Malhotra	  
et	  al,	  2006).	  	  
2.5.1  Polyani l ine  
Polyaniline	  (PANI)	  is	  an	  electroconductive	  polymer	  that	  is	  frequently	  used	  in	  biosensors	  due	  to	  
its	  high	  conductivity.	  PANI	  can	  be	  fabricated	  using	  a	  variety	  of	  methods;	  however,	  electrochemical	  
deposition	  is	  typically	  used	  for	  biosensor	  applications.	  In	  this	  method,	  a	  cyclic	  range	  of	  electric	  potentials	  
are	  applied	  by	  an	  electrode	  to	  a	  solution	  containing	  the	  aniline	  monomer.	  The	  potential	  causes	  the	  
aniline	  to	  polymerize	  and	  form	  a	  film	  on	  the	  surface	  of	  the	  electrode.	  	  The	  advantages	  of	  PANI	  over	  
other	  polymers	  include	  a	  higher	  thermal	  stability	  and	  a	  relatively	  low	  cost	  (Thomas,	  2012).	  	  In	  a	  study	  
that	  examined	  the	  electrochemical	  properties	  of	  PANI/CNT,	  polypyrrole/CNT,	  and	  PEDOT/CNT	  
composites,	  it	  was	  found	  that	  the	  PANI/CNT	  composite	  had	  the	  highest	  conductivity	  and	  largest	  
electrode	  specific	  capacitance	  (Peng	  et	  al,	  2007).	  It	  has	  also	  been	  suggested	  that	  unlike	  other	  
electroconductive	  polymers,	  PANI	  can	  have	  a	  synergistic	  relationship	  with	  carbon	  nanotubes	  that	  
improves	  electrical	  performance	  (Gajendran	  and	  Saraswathi,	  2008).	  	  
2.5.2  Polypyrrole  
Polypyrrole	  (PPY)	  is	  an	  electroconductive	  polymer	  that	  is	  biocompatible	  and	  easily	  manipulated.	  
Like	  PANI,	  it	  can	  also	  be	  electropolymerized	  at	  low	  oxidation	  potentials	  to	  form	  a	  film	  on	  the	  surface	  of	  
an	  electrode.	  It	  has	  small	  pores,	  which	  allow	  for	  the	  entrapment	  of	  enzymes	  or	  other	  molecules.	  These	  
pores	  also	  increase	  specificity	  by	  preventing	  larger	  molecules	  from	  interfering	  with	  the	  biosensor.	  PPY	  is	  
often	  used	  with	  CNT	  and	  has	  been	  shown	  to	  effectively	  wire	  the	  enzymes	  to	  the	  CNT	  and	  the	  electrode	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surface.	  This	  technique	  has	  been	  used	  in	  biosensors	  to	  monitor	  many	  analytes,	  including	  glucose	  (Peng	  
et	  al,	  2007,	  Gajendran	  and	  Saraswathi,	  2008,	  Balasubramanian	  and	  Burghard,	  2006).	  	  
2.5.3  PANI/Polypyrrole  Composites  
In	  recent	  years,	  researchers	  have	  begun	  to	  examine	  the	  possibility	  of	  using	  PANI/PPY	  
composites	  for	  the	  use	  in	  biosensors,	  in	  the	  hopes	  that	  they	  will	  work	  better	  together	  than	  either	  does	  
separately.	  This	  composite	  can	  be	  created	  by	  mixing	  the	  two	  monomers	  together	  in	  aqueous	  solution	  
and	  then	  electropolymerizing	  a	  film	  onto	  the	  surface	  of	  an	  electrode,	  or	  by	  polymerizing	  first	  one	  
monomer	  and	  then	  the	  other.	  PANI/PPY	  composites	  were	  used	  successfully	  to	  create	  biosensors	  for	  
organophosphates,	  uric	  acid,	  and	  hydrogen	  peroxide.	  In	  all	  cases,	  these	  composites	  allowed	  for	  the	  
creation	  of	  a	  highly	  sensitive,	  stable,	  and	  reproducible	  biosensor	  (Arslan,	  2008,	  Du	  et	  al.,	  2010,	  Cheng	  et	  
al,	  2007).	  When	  analyzed	  using	  scanning	  electron	  microscopy	  (SEM),	  Du	  et	  al.	  (2010)	  found	  that	  the	  
composite	  formed	  a	  well-­‐packed	  and	  homogenous	  layer	  with	  a	  porous	  nanostructure	  of	  an	  ideal	  size	  to	  
entrap	  enzymes.	  Cheng	  et	  al.	  (2007)	  noted	  that	  the	  composite	  creates	  a	  nanostructure	  with	  a	  large	  
surface	  area.	  Since	  PPY	  is	  limited	  by	  a	  relatively	  flat	  surface	  area,	  the	  addition	  of	  PANI	  corrects	  this	  
disadvantage.	  	  
2.5.4  Chitosan  
Chitosan	  is	  a	  non-­‐conductive,	  natural	  polymer	  found	  in	  the	  exoskeleton	  shells	  of	  shrimp,	  crabs	  
and	  other	  crustaceans.	  Chitosan	  is	  non-­‐toxic,	  biocompatible	  and	  biodegradable	  and	  has	  excellent	  film	  
forming	  properties	  (Sun,	  et	  al.,	  2009).	  Chitosan	  also	  has	  the	  potential	  for	  anti-­‐microbial	  properties.	  
Solutions	  and	  gel-­‐forms	  made	  of	  chitosan	  are	  antimicrobial,	  where	  as	  thin-­‐films	  were	  not	  effective	  in	  
preventing	  the	  growth	  of	  Escherichia	  coli,	  Staphylococcus	  aureus	  or	  Staphylococcus	  epidermidis	  (Foster,	  
et	  al.	  2011).	  This	  non-­‐conducting	  polymer	  has	  been	  used	  in	  biosensors	  as	  a	  way	  to	  immobilize	  enzymes.	  
Chitosan	  embodies	  many	  properties	  that	  will	  enhance	  the	  function	  of	  the	  biosensor.	  	  




Nafion	  is	  a	  synthetic	  co-­‐polymer	  with	  stable	  thermal	  and	  mechanical	  properties.	  Nafion	  films	  
have	  been	  widely	  used	  in	  biosensors	  because	  of	  its	  ion	  exchange	  and	  biocompatible	  properties.	  A	  
Nafion-­‐coated	  electrode	  allows	  for	  amperometric	  detection	  at	  low	  potentials.	  Nafion	  has	  antifouling	  
properties	  and	  works	  especially	  well	  with	  carbon	  nanotubes.	  A	  drawback	  to	  using	  this	  polymer	  is	  that	  it	  
does	  not	  eliminate	  interference	  from	  other	  molecules	  such	  as	  ascorbic	  acid	  (Wang	  et	  al.,	  2002).	  	  
2.5.6  Layer-­‐By-­‐Layer  Polymer  Deposit ion  
There	  are	  a	  variety	  of	  different	  techniques	  that	  can	  be	  used	  to	  deposit	  polymer	  films	  onto	  the	  
surface	  of	  the	  electrode.	  The	  layer-­‐by-­‐layer	  (LBL)	  polymer	  deposition	  method	  includes	  fabricating	  layers	  
of	  alternatively	  charged	  polymers	  on	  the	  electrode	  surface.	  The	  surface	  of	  the	  electrode	  is	  modified	  to	  
have	  either	  a	  positive	  or	  negative	  charge	  and	  then	  polymer	  layers	  are	  deposited	  one	  after	  another,	  
alternating	  charges.	  To	  deposit	  a	  layer	  of	  polymer,	  the	  electrode	  is	  dipped	  into	  polymer	  solution	  for	  a	  set	  
time	  period	  and	  then	  washed	  three	  times.	  The	  process	  is	  then	  repeated	  for	  each	  layer.	  The	  charge	  of	  a	  
polymer	  is	  dependent	  on	  its	  isoelectric	  point.	  At	  a	  pH	  above	  the	  polymer’s	  isoelectric	  point,	  the	  polymer	  
will	  be	  negatively	  charged	  whereas	  at	  a	  pH	  below	  the	  polymer’s	  isoelectric	  point,	  the	  polymer	  will	  be	  
positively	  charged	  (Amy	  Peterson,	  personal	  communication).	  	  
2.6  Conclusion    
A	  biosensor	  to	  monitor	  tumor	  size	  in	  GBM	  patients	  would	  allow	  medical	  personnel	  to	  alter	  a	  
patient’s	  treatment	  regimen	  quickly	  in	  response	  to	  treatment.	  It	  will	  also	  allow	  for	  monitoring	  of	  the	  
patient	  after	  remission,	  in	  order	  to	  ensure	  that	  any	  recurrence	  is	  found	  before	  the	  cancer	  becomes	  too	  
widespread.	  A	  successful	  project	  will	  create	  a	  biosensor	  that	  can	  effectively	  monitor	  tumor	  size	  and	  aid	  
in	  extending	  the	  lives	  of	  patients	  with	  GBM.	  In	  addition,	  because	  increased	  concentrations	  of	  lactate	  are	  
produced	  by	  all	  types	  of	  tumor	  cells,	  this	  technology	  could	  be	  used	  to	  monitor	  the	  progression	  of	  other	  
types	  of	  cancer.	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3.  Project  Strategy  
To	  begin	  the	  design	  process	  for	  this	  biosensor,	  a	  client	  statement	  was	  created	  in	  order	  to	  focus	  the	  
design	  to	  meet	  the	  desired	  functions	  of	  the	  biosensor.	  From	  this	  statement,	  a	  list	  of	  design	  objectives	  
was	  created	  as	  a	  way	  to	  evaluate	  our	  design	  alternatives	  based	  on	  how	  well	  the	  design	  alternatives	  met	  
each	  objective.	  Certain	  constraints	  were	  applied	  to	  the	  project,	  such	  as	  a	  budget	  of	  $468	  and	  eight	  
months	  to	  complete	  the	  project.	  
3.1  Cl ient  Statement  
  
At	  the	  beginning	  of	  the	  design	  process	  the	  team	  was	  given	  the	  initial	  client	  statement	  of:	  	  
Create	  a	  biosensor	  that	  will	  last	  long-­‐term	  to	  detect	  multiple	  metabolites.	  This	  biosensor	  will	  
monitor	  the	  progression	  of	  Glioblastoma	  Multiforme	  to	  determine	  the	  effectiveness	  of	  treatment	  on	  
tumor	  size.	  
As	  the	  project	  progressed,	  the	  team	  revised	  and	  refined	  the	  client	  statement	  to	  be:	  
Create	  a	  biosensor	  that	  will	  last	  for	  at	  least	  two	  week,	  at	  physiological	  conditions,	  to	  detect	  
concentrations	  of	  lactate	  in	  patients	  with	  Glioblastoma	  Multiforme.	  This	  biosensor	  will	  be	  able	  to	  
correlate	  metabolite	  concentrations	  with	  tumor	  size	  in	  order	  to	  monitor	  the	  progression	  of	  GBM.	  The	  
long-­‐term	  clinical	  application	  of	  this	  device	  is	  to	  be	  used	  in	  vivo	  to	  monitor	  the	  effectiveness	  of	  treatment	  
on	  the	  tumor.	  	  
This	  client	  statement	  was	  the	  basis	  of	  the	  design	  process	  and	  guided	  the	  team	  in	  designing	  a	  
biosensor	  to	  monitor	  GBM.	  	  
3.2  Objectives  
The	  objectives	  for	  this	  project	  were	  derived	  from	  the	  client	  statement	  and	  through	  extensive	  
background	  research.	  A	  list	  of	  the	  objectives,	  ranked	  in	  order	  of	  importance,	  is	  shown	  below:	  
1) Specific	  








7) Long-­‐lasting	   	  	  
The	  first	  and	  foremost	  objective	  was	  that	  the	  biosensor	  must	  be	  specific	  and	  detect	  a	  signal	  only	  
from	  the	  metabolites	  of	  interest.	  Interference	  from	  other	  molecules,	  such	  as	  ascorbic	  acid	  and	  
acetaminophen	  (Yoo	  and	  Li,	  2010),	  would	  cause	  the	  current	  produced	  by	  the	  biosensor	  to	  be	  
disproportional	  to	  the	  actual	  metabolite	  level.	  Minimizing	  the	  noise	  and	  interference	  from	  other	  
metabolites	  would	  ensure	  that	  the	  biosensor	  reflects	  the	  actual	  metabolite	  level.	  The	  biosensor	  must	  
also	  be	  accurate	  at	  detecting	  the	  concentrations	  of	  lactate	  and	  translating	  it	  into	  a	  corresponding	  
current	  output.	  This	  is	  important	  because	  clinicians	  must	  be	  able	  to	  use	  the	  biosensor	  as	  a	  tool	  to	  judge	  
the	  efficacy	  of	  therapies	  on	  the	  tumor.	  Sensitivity	  is	  also	  important	  in	  biosensor	  design.	  In	  order	  to	  be	  
effective,	  the	  biosensor	  must	  be	  sensitive	  enough	  to	  detect	  physiological	  levels	  of	  the	  metabolites	  of	  
interest,	  which	  range	  from	  0.79	  mM	  in	  healthy	  patients	  to	  0.97mM	  in	  patients	  with	  GBM	  (Holroyde,	  
1979).	  The	  biosensor	  was	  also	  designed	  to	  produce	  reproducible	  results	  so	  that	  it	  can	  be	  used	  multiple	  
times	  with	  the	  same	  performance	  outcomes.	  The	  electrical	  current	  produced	  from	  each	  concentration	  
of	  lactate	  should	  be	  constant	  with	  multiple	  tests	  of	  the	  biosensor.	  We	  would	  expect	  the	  biosensor	  to	  
have	  reproducible	  results	  over	  time	  as	  well	  as	  reproducible	  results	  between	  multiple	  biosensors	  with	  the	  
same	  fabrication	  method.	  The	  device	  needs	  to	  be	  easy	  to	  manufacture	  so	  that	  it	  can	  actually	  be	  
implemented	  in	  laboratory	  and	  clinical	  settings.	  This	  means	  that	  the	  device	  must	  be	  relatively	  simple	  to	  
fabricate.	  The	  cost	  of	  manufacturing	  prototypes	  and	  the	  final	  designs	  should	  also	  remain	  relatively	  low	  
so	  that	  this	  project	  can	  stay	  on	  budget	  and	  so	  that	  the	  final	  cost	  for	  patients	  is	  reasonable.	  The	  
biosensor	  should	  be	  biocompatible	  and	  minimize	  the	  foreign	  body	  response	  by	  the	  immune	  system.	  
When	  the	  human	  body	  detects	  a	  foreign	  object	  such	  as	  a	  biosensor,	  the	  immune	  system	  reacts	  by	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forming	  a	  capsule	  of	  fibrous	  tissue	  around	  the	  object.	  It	  is	  vital	  that	  the	  biosensor	  minimize	  this	  
response	  to	  avoid	  encapsulation.	  Encapsulation	  could	  limit	  the	  availability	  of	  lactate	  to	  the	  biosensor	  
and	  decrease	  the	  ability	  of	  the	  biosensor	  to	  effectively	  monitor	  metabolite	  concentrations	  for	  an	  
extended	  period	  of	  time.	  The	  biosensor	  should	  be	  long	  lasting	  once	  implanted	  into	  the	  body.	  An	  ideal	  
biosensor	  would	  last	  for	  several	  months	  to	  years	  inside	  the	  body.	  Implanting	  a	  biosensor	  is	  a	  somewhat	  
invasive	  procedure	  and	  minimizing	  the	  need	  for	  this	  procedure	  would	  benefit	  not	  only	  the	  patient,	  but	  
also	  keep	  the	  costs	  of	  patient	  monitoring	  down.	  In	  order	  for	  the	  biosensor	  can	  remain	  functional,	  it	  
should	  function	  well	  at	  physiological	  conditions,	  resist	  degradation,	  and	  maintain	  enzyme	  activity.	  	  
3.3  Constraints  
The	  design	  of	  the	  lactate	  biosensor	  was	  limited	  by	  some	  constraints.	  The	  first	  major	  constraint	  
was	   that	   the	  biosensor	   could	  not	  be	   cytotoxic.	   This	   forced	  us	   to	  only	   select	  materials	   that	  have	  been	  
proven	  to	  be	  biocompatible.	  The	  biosensor	  design	  was	  also	  constrained	  by	  the	  equipment	  available.	  The	  
biosensor	  had	  to	  be	  easily	  used	  with	  the	  AUTOLAB	  potentiostat	  found	  in	  Dr.	  Susan	  Zhou’s	  lab.	  The	  costs	  
for	   the	  materials	   for	  all	  prototype	  designs	  were	   limited	   to	  a	  budget	  of	  $156	  per	  person,	   for	  a	   total	  of	  
$468.	   	   The	   time	   to	   complete	   the	   design	   and	   test	   prototypes	  was	   limited	   to	   the	   2013-­‐2014	   academic	  
year.	  
3.4  Project  Approach  
This	   project	   is	   based	   upon	   a	  MQP	   project	   completed	   in	   the	   2012-­‐2013	   academic	   year,	  which	  
designed	  and	  tested	  a	  biosensor	  to	  monitor	  lactate	  levels.	  The	  approach	  for	  this	  project	  was	  to	  redesign	  
the	   existing	   lactate	   biosensor.	   The	   goal	   of	   this	   project	   was	   to	   create	   a	   biosensor	   that	   had	   improved	  
sensitivity,	   reproducibility,	   and	   response	   time	  when	   compared	   to	   the	   previous	   design.	   In	   order	   to	   do	  
this,	   the	   literature	   was	   reviewed	   to	   examine	  which	  materials	   would	   be	   advantageous	   for	   use	   in	   this	  
project.	   In	   an	   iterative	   testing	   process,	   each	   component	   of	   the	   design	   was	   tested	   for	   effectiveness.	  
Scanning	   electron	  microscopy	  was	   used	   to	   evaluate	   the	   uniformity	   of	   the	   films	   for	   two	  of	   the	   design	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alternatives.	  The	  final	  design	  was	  validated	  by	  creating	  a	  standard	  curve	  of	  current	  output	  as	  a	  function	  
of	   lactate	   concentration,	   and	   then	  using	   that	   curve	   to	  estimate	   the	   concentration	  of	   lactate	   in	  media	  
that	   had	   been	   cultured	  with	  U87mg	   cells.	   Finally,	   the	   biosensor’s	   response	   to	   changing	   lactate	   levels	  
over	  time	  was	  tested.	  	  	  
There	  were	  some	  technical	  challenges	  that	  had	  to	  be	  overcome	  over	  the	  duration	  of	  this	  project.	  
The	  first	  challenge	  was	  the	  group’s	  inexperience	  in	  the	  field	  of	  electrochemistry.	  The	  group	  had	  to	  learn	  
and	  perfect	  the	  approach	  and	  techniques	  required	  to	  successfully	  complete	  electrochemical	  
experiments.	  Equipment	  availability	  due	  to	  other	  researchers	  and	  maintenance	  contributed	  to	  some	  
delays.	  The	  major	  technical	  issue	  the	  team	  faced	  was	  electrochemical	  equipment	  errors.	  During	  testing	  
the	  equipment	  was	  outputting	  noisy	  and	  inconsistent	  data.	  When	  a	  clean	  glassy	  carbon	  electrode	  was	  
tested	  in	  PBS,	  the	  three	  trials	  conducted	  were	  very	  inconsistent.	  As	  a	  result	  of	  the	  issue,	  the	  group	  
traveled	  to	  the	  University	  of	  Connecticut	  to	  perform	  testing.	  The	  ability	  to	  complete	  experiments	  was	  
hindered	  by	  travel	  time	  and	  the	  availability	  of	  the	  researcher	  the	  team	  worked	  with.	  These	  technical	  
issues	  prevented	  the	  team	  from	  progressing	  as	  far	  as	  the	  team	  had	  hoped.	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4.  Design  
4.1	  Need	  Analysis	  
	   Current	  methods	  for	  the	  treatment	  of	  Glioblastoma	  Multiforme	  such	  as	  MRI	  and	  CT	  scans	  are	  
expensive,	  inconvenient,	  and	  do	  not	  detect	  small	  or	  diffuse	  tumors.	  This	  creates	  a	  need	  for	  an	  effective	  
method	  to	  monitor	  GBM	  that	  can	  be	  used	  frequently	  and	  long-­‐term.	  
	   In	  order	  to	  create	  an	  effective	  biosensor	  to	  monitor	  lactate	  in	  GBM	  patients,	  many	  different	  
design	  alternatives	  were	  created	  and	  evaluated.	  In	  order	  to	  evaluate	  these	  design	  alternatives,	  the	  
functions	  and	  specifications	  were	  analyzed	  to	  determine	  the	  most	  effective	  design.	  The	  biosensor	  must	  
be	  able	  to	  determine	  the	  level	  of	  lactate	  in	  order	  to	  be	  able	  to	  accurately	  monitor	  the	  progression	  of	  
GBM.	  
In	  order	  for	  the	  biosensor	  to	  be	  considered	  effective,	  it	  will	  need	  to	  satisfy	  the	  needs	  of	  the	  client,	  
which	  are	  as	  follows:	  
• Accurate:	  The	  biosensor	  should	  be	  able	  to	  produce	  accurate	  results	  for	  the	  analysis	  of	  
metabolite	  concentration.	  
• Specific:	  The	  device	  must	  be	  able	  to	  recognize	  lactate	  concentrations	  without	  being	  affected	  by	  
any	  other	  metabolite	  levels	  in	  the	  tissue.	  
• Reproducible:	  The	  biosensor	  should	  be	  able	  to	  be	  reproduced	  and	  the	  same	  results	  should	  be	  
able	  to	  be	  replicated.	  
• Sensitive:	  The	  biosensor	  readings	  should	  be	  able	  to	  adjust	  with	  increasing	  or	  decreasing	  levels	  of	  
lactate	  within	  the	  tissue.	  
• Biocompatible:	  The	  system	  needs	  to	  be	  able	  to	  be	  implanted	  into	  the	  body	  in	  future	  studies	  and	  
not	  induce	  a	  foreign	  body	  response.	  
In	  addition	  to	  the	  design	  needs	  given	  by	  the	  client,	  desired	  properties	  must	  be	  considered,	  
which	  are:	  
• Long-­‐lasting:	  The	  biosensor	  should	  be	  able	  to	  work	  in	  the	  body	  for	  weeks	  to	  months.	  
• Implantable:	  The	  system	  should	  be	  able	  to	  be	  implanted	  into	  the	  body	  for	  future	  in	  vivo	  studies	  
with	  minimally	  invasive	  techniques.	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• Quick	  response	  time:	  The	  biosensor	  should	  be	  able	  to	  detect	  the	  metabolite	  concentration	  
within	  seconds	  of	  a	  change	  in	  lactate	  concentration.	  
• Easy	  to	  manufacture:	  Eventually,	  this	  design	  should	  be	  easy	  to	  manufacture	  in	  order	  to	  produce	  
the	  device	  in	  large	  volume.	  
Through	  understanding	  and	  prioritizing	  the	  needs	  and	  wants	  of	  the	  client	  we	  can	  rank	  which	  
objectives	  should	  be	  satisfied	  first	  and	  the	  objectives	  that	  we	  can	  attempt	  to	  satisfy	  in	  future	  designs.	  
4.2	  Functions	  
	   The	  overall	  function	  of	  the	  biosensor	  is	  to	  frequently	  measure	  lactate	  concentration	  in	  order	  to	  
monitor	  the	  progression	  of	  GBM.	  Sub-­‐functions	  are	  necessary	  for	  our	  biosensor	  in	  order	  to	  satisfy	  the	  
main	  function	  of	  our	  design.	  Using	  a	  black	  box	  diagram,	  the	  sub-­‐functions	  necessary	  for	  our	  biosensor	  to	  
be	  considered	  effective	  are	  shown.	  The	  black	  box	  diagram	  shown	  in	  Figure	  4	  displays	  the	  initial	  input	  of	  
unknown	  metabolite	  concentration	  and	  the	  final	  output	  as	  the	  current	  progression	  status	  of	  the	  GBM	  
cells	  that	  are	  being	  monitored.	  The	  black	  box	  contains	  sub-­‐functions	  which	  are	  needed	  to	  convert	  the	  






Figure	  4:	  Black	  Box	  of	  Biosensor	  Functions	  
A	  black	  box	  diagram	  displaying	  all	  functions	  and	  sub-­‐functions	  necessary	  for	  our	  device	  to	  be	  effective	  
	   	  
As	  shown	  previously,	  the	  black	  box	  diagram	  has	  two	  steps.	  The	  sub-­‐functions	  of	  the	  biosensor	  take	  
in	  the	  voltage	  applied	  and	  the	  unknown	  metabolite	  concentration	  and	  convert	  this	  to	  an	  electrical	  signal	  
output	  that	  is	  then	  sent	  to	  a	  processor.	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4.3  Specifications	  
Specifications	  that	  the	  design	  must	  meet	  are	  discussed	  below.	  
4.3.1	  Metabolites	  
The	  biosensor	  needs	  to	  be	  able	  to	  measure	  the	  concentration	  of	  lactate	  in	  order	  to	  effectively	  
monitor	  the	  progression	  of	  GBM.	  GBM	  tumor	  cells	  release	  excess	  lactate	  that	  enters	  into	  the	  blood	  
stream	  and	  becomes	  systemic.	  The	  amount	  of	  lactate	  released	  is	  proportional	  to	  GBM	  tumor	  size,	  which	  
makes	  the	  analysis	  of	  lactate	  a	  suitable	  way	  to	  determine	  the	  progression	  of	  GBM.	  The	  concentration	  of	  
lactate	  in	  a	  healthy	  adult	  is	  approximately	  0.79	  mM	  and	  the	  concentration	  of	  lactate	  is	  0.97	  mM	  in	  a	  
patient	  with	  cancer	  (Holroyde,	  1979).	  
4.3.2	  Enzymes	  	  
In	  order	  to	  enhance	  biosensor	  function,	  the	  enzyme	  lactate	  oxidase	  (LOX)	  will	  be	  used.	  Lactate	  
oxidase	  is	  used	  to	  catalyze	  the	  breakdown	  of	  lactate	  into	  hydrogen	  peroxide	  and	  then	  free	  electrons,	  as	  
shown	  in	  the	  equation	  below,	  which	  reduces	  response	  time.	  	  
𝐿𝑎𝑐𝑡𝑎𝑡𝑒 +   𝑂! !"# 𝑃𝑦𝑟𝑢𝑣𝑎𝑡𝑒 +  	  𝐻!0! 	  
	   𝐻!𝑂! !"#$%&' 2𝐻! + 𝑂! + 2𝑒! 	  
	  
Using	  lactate	  oxidase	  increases	  the	  specificity	  of	  the	  biosensor.	  Other	  analytes	  such	  as	  glucose	  
and	  glutamate	  follow	  the	  same	  breakdown	  pathway;	  however	  lactate	  oxidase	  only	  catalyzes	  the	  
breakdown	  of	  lactate.	  	  	  
4.3.3  E lectroconductive  Polymers  
Conductive	  polymers	  can	  enhance	  biosensor	  function	  by	  increasing	  selectivity	  and	  decreasing	  
response	  time.	  The	  pore	  size	  of	  a	  polymer	  film	  determines	  what	  size	  molecules	  are	  able	  to	  pass	  through	  
and	  reach	  the	  electrode	  surface.	  Adding	  a	  polymer	  film	  to	  the	  electrode	  decreases	  interference	  by	  
filtering	  out	  any	  molecules	  that	  are	  too	  large	  to	  pass	  through	  its	  pores.	  Conductive	  polymers,	  such	  as	  
polypyrrole,	  polyaniline	  and	  Nafion,	  allow	  electrons	  to	  easily	  pass	  through	  and	  reach	  the	  electrode	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surface,	  decreasing	  biosensor	  response	  time.	  Lactate	  oxidase	  was	  crosslinked	  with	  glutaraldehyde	  to	  the	  
polymer	  films,	  because	  preliminary	  testing	  revealed	  that	  the	  lactate	  oxidase	  leached	  out	  of	  the	  
biosensor	  if	  it	  was	  not	  crosslinked.	  
4.3.4	  Sensitivity	  and	  Range	  
The	  sensitivity	  and	  range	  of	  the	  biosensor	  is	  based	  on	  physiological	  lactate	  levels	  found	  in	  healthy	  
adults	  and	  GBM	  patients.	  The	  biosensor	  must	  detect	  the	  concentration	  range	  of	  0.79mM	  lactate	  found	  
in	  healthy	  patients	  to	  0.97mM	  lactate	  which	  is	  found	  in	  patients	  with	  GBM.	  An	  ideal	  range	  for	  this	  
biosensor	  would	  be	  between	  0-­‐10	  mM.	  The	  biosensor	  also	  needs	  to	  be	  sensitive	  enough	  to	  determine	  
the	  minute	  changes	  in	  the	  concentration	  of	  lactate	  over	  time.	  	  
4.3.5	  Dimensions	  
The	  glassy	  carbon	  electrodes	  provided	  by	  the	  client	  have	  a	  diameter	  of	  3mm.	  The	  area	  of	  
contact	  between	  the	  electrode	  and	  the	  film	  determines	  the	  amount	  of	  polymer	  and	  enzyme	  used	  in	  
creating	  the	  film.	   	  
4.3.6	  Stability	  
Enzymatic	  biosensors	  are	  generally	  stable	  for	  approximately	  21	  days,	  based	  on	  a	  literature	  
review,	  but	  the	  length	  of	  stability	  of	  the	  biosensor	  is	  highly	  dependent	  on	  the	  storage	  temperature.	  For	  
our	  biosensor,	  we	  hope	  to	  achieve	  stability	  of	  the	  biosensor	  for	  21	  days.	  Ideally,	  this	  biosensor	  will	  be	  
able	  to	  function	  on	  the	  scale	  of	  months	  to	  years,	  to	  minimize	  the	  number	  of	  implantations	  of	  the	  device.	  
4.4	  Design	  Alternatives	  
Design	  alternatives	  were	  created	  involving	  different	  combinations	  of	  conductive	  polymers,	  along	  
with	  the	  enzyme	  and	  a	  crosslinking	  agent.	  Preliminary	  testing	  was	  performed	  on	  the	  design	  alternatives	  
in	  order	  to	  determine	  the	  design	  components	  that	  were	  the	  most	  efficient	  in	  detecting	  the	  changes	  in	  
the	  concentration	  of	  lactate.	  





	  	   	  
	  
	  
	   	  	  
	  
	  
	   	   	   	  	  
	   	  	  
Lactate	  Oxidase	  Cross-­‐Linked	  With	  
Glutaraldehyde 
4.4.1	  Single	  Electroconductive	  Polymer	  
The	  team	  used	  both	  polypyrrole	  and	  polyaniline	  as	  the	  chosen	  polymers	  for	  the	  biosensor	  film.	  
For	  a	  film	  layer	  of	  polypyrrole,	  the	  team	  used	  a	  clean	  glassy	  carbon	  electrode	  and	  polymerized	  pyrrole	  
onto	  the	  surface	  of	  the	  electrode.	  To	  create	  the	  layer	  of	  polyaniline,	  the	  team	  used	  a	  clean	  glassy	  
carbon	  electrode	  and	  polymerized	  aniline	  onto	  the	  surface.	  On	  both	  of	  these	  designs,	  as	  seen	  in	  Figure	  
5,	  the	  polymer	  was	  crosslinked,	  using	  glutaraldehyde,	  with	  the	  enzyme.	  	  
	  












Figure	  5:	  Single	  Layer	  Polymer	  Deposition	  
Single	  layer	  of	  PPY	  or	  PANI	  with	  the	  lactate	  oxidase	  crosslinked	  with	  glutaraldehyde	  
4.4.2	  Layered	  Electroconductive	  Polymers	  
Electroconductive	  polymers	  were	  layered	  one	  on	  top	  of	  the	  other.	  For	  the	  first	  design,	  pyrrole	  
was	  polymerized	  onto	  the	  surface	  of	  the	  clean	  electrode.	  The	  same	  electrode	  was	  then	  used	  to	  
polymerize	  aniline	  onto	  the	  surface	  for	  a	  film	  consisting	  of	  a	  polypyrrole	  and	  polyaniline	  layered	  film	  
coating.	  The	  top	  coating,	  polyaniline,	  was	  then	  crosslinked,	  using	  glutaraldehyde,	  with	  the	  enzyme.	  The	  
second	  design	  used	  the	  same	  logic,	  but	  polymerized	  aniline	  onto	  the	  clean	  surface	  of	  the	  electrode	  
before	  then	  polymerizing	  pyrrole	  onto	  the	  surface.	  The	  top	  coating	  of	  polypyrrole	  was	  then	  crosslinked,	  
using	  glutaraldehyde,	  with	  the	  enzyme	  as	  seen	  in	  Figure	  6.	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Figure	  6:	  Dual	  Layer-­‐by-­‐Layer	  Polymer	  Deposition	  
Layered	  PPY	  and	  PANI	  with	  the	  lactate	  oxidase	  crosslinked	  with	  glutaraldehyde	  
4.4.3  Co-­‐Polymer  Blend  
Based	  on	  the	  literature,	  both	  polypyrrole	  and	  polyaniline	  showed	  an	  increased	  current	  
response	  because	  of	  their	  conductive	  properties.	  Blending	  the	  two	  polymers	  together	  may	  have	  an	  
increased	  current	  response;	  therefore	  this	  design	  was	  considered	  to	  be	  an	  alternative	  as	  well,	  as	  seen	  
in	  Figure	  7.	  The	  pyrrole	  and	  aniline	  were	  polymerized	  onto	  the	  electrode	  surface	  as	  a	  co-­‐polymer	  blend.	  
The	  co-­‐polymer	  was	  then	  crosslinked	  with	  the	  enzyme	  using	  glutaraldehyde.	  
	  	  	  
	  
	  
	  	  	  	  	  	  	  
Figure	  7:	  Co-­‐polymer	  Blend	  Deposition	  
A	  co-­‐polymer	  blend	  of	  PPY	  and	  PANI	  with	  the	  lactate	  oxidase	  crosslinked	  with	  glutaraldehyde	  
4.5	  Design	  Alternative	  Evaluation	  
	   To	  evaluate	  the	  design	  alternatives,	  the	  team	  performed	  preliminary	  testing	  on	  the	  designs	  to	  
see	  which	  design	  had	  the	  greatest	  sensitivity	  to	  the	  different	  lactate	  concentrations.	  This	  preliminary	  
testing	  consisted	  of	  amperometry	  and	  cyclic	  voltammetry	  tests	  with	  multiple	  known	  concentrations	  of	  
	   PPY-­‐PANI	  Blend 
	   Glassy	  Carbon	  Electrode	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lactate.	  After	  testing,	  the	  final	  design	  was	  chosen	  due	  to	  the	  highest	  current	  output	  in	  the	  amperometry	  
and	  cyclic	  voltammetry	  for	  a	  given	  lactate	  concentration.	  
4.6  F inal   Design  
The	  final	  design	  that	  was	  chosen	  was	  the	  PPY-­‐PANI-­‐LOX	  on	  the	  glassy	  carbon	  electrode.	  This	  
design,	  which	  layered	  the	  polymers	  by	  polymerizing	  the	  pyrrole	  onto	  the	  electrode	  followed	  by	  the	  
addition	  of	  polyaniline	  with	  lactate	  oxidase	  crosslinked	  to	  surface	  using	  glutaraldehyde,	  proved	  to	  be	  the	  
most	  responsive	  in	  the	  preliminary	  testing.	  After	  the	  preliminary	  testing,	  the	  final	  design,	  PPY-­‐PANI-­‐LOX	  
was	  evaluated	  by	  testing	  with	  various	  cell	  counts	  of	  GBM	  cells	  in	  media	  and	  through	  the	  addition	  of	  
lactate	  over	  time	  to	  determine	  the	  response	  time	  of	  the	  biosensor.	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5.  Methods  
An	  iterative	  process	  was	  used	  to	  add	  and	  test	  components	  of	  our	  lactate	  biosensor.	  The	  glassy	  
carbon	  electrode,	  polypyrrole	  deposition,	  polyaniline	  deposition,	  and	  addition	  of	  enzymes	  were	  all	  
tested	  separately	  to	  determine	  the	  effects	  that	  each	  new	  material	  had	  on	  overall	  biosensor	  
functionality.	  This	  section	  describes	  the	  fabrication	  of	  the	  different	  biosensor	  components,	  cell	  culture,	  
testing	  and	  validation	  procedures,	  and	  methods	  of	  data	  analysis.	  	  
5.1  Fabrication  of  Biosensor  
Glassy	  carbon	  electrodes	  (GCE)	  with	  a	  diameter	  of	  3mm	  were	  polished	  in	  sequential	  steps	  of	  1	  
µm	  and	  0.3	  µm	  alumina	  slurry,	  followed	  by	  sonication	  for	  15	  minutes	  in	  deionized	  water.	  For	  all	  
electrochemical	  experiments,	  the	  glassy	  carbon	  electrode	  (working	  electrode)	  was	  used	  with	  an	  Ag/AgCl	  
reference	  electrode	  and	  a	  platinum	  counter	  electrode.	  	  An	  AUTOLAB	  potentiostat	  (Metrohm)	  and	  GPES	  
software	  were	  used	  to	  control	  the	  electrical	  current	  and	  voltage	  running	  through	  the	  working	  electrode	  
and	  to	  record	  data.	  The	  same	  experimental	  set-­‐up,	  seen	  in	  Figure	  8,	  was	  used	  for	  all	  experiments.	  After	  

















Figure	  8:	  Biosensor	  Set-­‐up	  
Set-­‐up	  of	  biosensor/working	  electrode	  (red),	  platinum	  counter	  electrode	  (black),	  Ag/AgCl	  reference	  electrode	  
(blue).	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To	  create	  the	  polypyrrole	  film	  on	  the	  surface	  of	  the	  GCE,	  7	  µL	  (0.01M)	  of	  pyrrole	  (Sigma-­‐Aldrich)	  
was	  added	  to	  10	  mL	  of	  0.01	  M	  phosphate	  buffered	  saline	  (PBS)	  that	  had	  previously	  been	  degassed	  by	  
nitrogen	  bubbling	  for	  15	  minutes	  (Li	  et	  al.,	  2005).	  The	  pyrrole	  was	  polymerized	  to	  form	  polypyrrole	  on	  
the	  surface	  of	  the	  GCE	  by	  using	  galvanostatic	  deposition.	  Polymerization	  occurred	  at	  a	  current	  of	  25	  
mA/cm2	  for	  120	  seconds.	  	  
After	  pyrrole	  polymerization	  on	  the	  electrode	  surface,	  a	  polyaniline	  (PANI)	  film	  was	  created	  on	  
top	  of	  the	  pyrrole	  film	  by	  polymerizing	  45	  µL	  of	  aniline	  monomer	  in	  degassed	  0.1M	  PBS	  of	  pH	  3.5	  
(Gaikwad	  et	  al.,	  2006).	  Nine	  cycles	  of	  cyclic	  voltammetry	  between	  0.00	  and	  0.95	  V	  were	  used	  to	  
polymerize	  the	  aniline.	  	  
5	  µL	  of	  0.1%	  glutaraldehyde	  (Sigma-­‐Aldrich)	  was	  placed	  on	  top	  of	  the	  layered	  polymers	  and	  left	  
to	  dry	  at	  room	  temperature	  for	  30	  minutes.	  5	  µL	  of	  lactate	  oxidase	  enzyme(LOX)	  	  (2.9	  mg/mL,	  Sigma-­‐
Aldrich)	  was	  added	  on	  top	  of	  the	  pyrrole-­‐glutaraldehyde	  electrode.	  The	  glutaraldehyde	  served	  to	  
crosslink	  the	  pyrrole	  to	  the	  enzyme.	  	  
5.2  Cell   Culture  
Human	  glioblastoma	  cells	  (U87mg),	  harvested	  from	  a	  47	  year	  old	  male	  patient	  and	  stabilized	  for	  
cell	  culture,	  were	  cultured	  in	  Dulbecco’s	  Modified	  Eagle’s	  Medium	  (DMEM)	  containing	  10%	  fetal	  bovine	  
serum,	  1%	  L-­‐glutamine,	  1%	  penicillin-­‐streptomycin,	  1%	  Non-­‐Essential	  Amino	  Acids	  for	  48	  hours.	  	  
5.3  Testing  Procedures  
The	  individual	  components	  of	  our	  biosensors	  (GCE,	  PANI,	  PPY,	  LOX)	  were	  added	  in	  an	  iterative	  
process	  to	  ensure	  that	  each	  new	  design	  component	  improved	  the	  functionality	  of	  the	  biosensors.	  
Therefore,	  we	  tested	  the	  effects	  of	  different	  concentrations	  of	  lactate	  (0.05	  mM,	  0.1	  mM,	  1	  mM,	  10	  
mM,	  25	  mM)	  on	  the	  plain	  GCE,	  GCE	  +	  PPY,	  GCE	  +	  PANI,	  GCE+PPY+LOX,	  GCE+PANI+LOX,	  GCE+PANI+PPY,	  
GCE+PPY+PANI,	  and	  GCE+PANI+PPY+LOX.	  To	  measure	  the	  effects	  of	  lactate	  on	  these	  biosensor	  design	  
iterations,	  we	  used	  the	  electrode	  setup,	  AUTOLAB,	  and	  GPES	  software	  as	  described	  in	  Section	  5.1.	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For	  each	  test,	  degassed	  PBS	  containing	  0.05mM,	  0.1mM,	  1mM,	  10mM,	  or	  25mM	  of	  lactate	  was	  
placed	  into	  the	  electrochemical	  cell.	  A	  new	  solution	  was	  used	  for	  each	  test.	  To	  measure	  the	  maximum	  
current	  output	  of	  the	  biosensors	  in	  response	  to	  lactate,	  we	  used	  the	  Autolab	  to	  perform	  amperometry,	  
in	  which	  the	  voltage	  is	  held	  constant	  at	  0.2	  V	  and	  the	  current	  changes	  as	  a	  function	  of	  analyte	  
concentration.	  We	  also	  used	  cyclic	  voltammetry	  (cycling	  between	  -­‐0.4	  and	  +0.6V,	  10	  cycles)	  to	  gauge	  
overall	  biosensor	  performance	  as	  a	  function	  of	  analyte	  concentration.	  The	  biosensors’	  response	  to	  
increasing	  lactate	  concentrations	  over	  time	  was	  performed	  by	  adding	  different	  volumes	  of	  25	  mM	  
lithium	  lactate	  solution	  in	  PBS	  over	  time	  (see	  Table	  2).	  	  
5.4  Val idation  of  Biosensor     
Lactate	  assays	  (Sigma-­‐Aldrich)	  were	  used	  to	  determine	  the	  concentration	  of	  lactate	  present	  in	  
the	  cell	  media.	  This	  was	  compared	  to	  the	  concentration	  calculated	  based	  on	  the	  biosensor	  reading	  in	  
order	  to	  determine	  biosensor	  accuracy.	  	  
The	  three	  dimensional	  structure	  of	  the	  PPY	  and	  PPY-­‐PANI	  films	  were	  examined	  using	  scanning	  
electron	  microscopy.	  
5.5  Data  Analysis  
Three	  separate	  trials	  were	  completed	  for	  all	  experiments.	  All	  graphs	  shown	  represent	  the	  average	  of	  
the	  absolute	  values	  for	  the	  three	  trials	  for	  each	  condition.	  Standard	  curves	  were	  created	  in	  excel	  by	  
fitting	  a	  linear	  regression	  to	  collected	  data	  points.	  The	  standard	  deviations	  for	  comparative	  ELISA	  and	  
amperometry	  results	  were	  also	  calculated	  using	  excel.	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6.  Results  
In	  order	  to	  tailor	  our	  biosensor	  to	  be	  sensitive	  to	  the	  in	  vitro	  concentrations	  of	  lactate	  typically	  
produced	  by	  glioblastoma	  cells,	  U87mg	  human	  glioblastoma	  cells	  were	  cultured	  for	  48	  hours.	  The	  media	  
was	  then	  collected.	  An	  ELISA	  measured	  the	  different	  lactate	  concentrations	  produced	  by	  different	  
numbers	  of	  U87mg	  cells	  seeded,	  as	  seen	  in	  Table	  1.	  These	  concentrations	  were	  calculated	  by	  using	  an	  
equation	  derived	  from	  a	  standard	  curve,	  seen	  in	  Appendix	  2.	  	  
Table	  1:	  Concentration	  of	  Lactate	  Produced	  by	  Glioblastoma	  Cells	  














Multiple	  design	  iterations	  were	  successfully	  fabricated	  and	  tested.	  In	  order	  to	  make	  a	  PPY	  film	  
with	  a	  strong	  current	  response,	  we	  tested	  four	  different	  electropolymerization	  methods.	  Based	  on	  the	  
results,	  seen	  in	  Appendix	  3,	  	  it	  was	  decided	  that	  polymerizing	  a	  solution	  of	  0.01M	  pyrrole	  by	  holding	  the	  
current	  constant	  at	  25mA/cm2	  for	  120	  seconds	  would	  produce	  a	  PPY	  film	  with	  the	  highest	  current	  
output	  in	  response	  to	  lactate.	  Li	  et	  al.	  (2005)	  had	  stated	  that	  this	  methodology	  would	  lead	  to	  a	  PPY	  film	  
thickness	  of	  100	  nm.	  The	  methodology	  for	  creating	  the	  PANI	  film	  was	  based	  on	  the	  protocol	  from	  
Viswanathan	  et	  al.	  2009,	  in	  which	  the	  voltage	  applied	  to	  the	  working	  electrode	  was	  cycled	  between	  +0.0	  
and	  +0.95	  V	  for	  multiple	  cycles.	  Robberg	  et	  al.	  (1998)	  state	  that	  the	  thickness	  of	  the	  PANI	  film	  formed	  is	  
dependent	  on	  the	  total	  charge/area,	  where	  1	  Coulomb/cm2	  will	  result	  in	  a	  film	  thickness	  of	  50	  µm.	  Using	  
this	  equation	  and	  the	  oxidation	  and	  reduction	  charges	  for	  each	  cycle	  given	  by	  GPES,	  we	  calculated	  that	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for	  nine	  cycles,	  the	  thickness	  of	  PANI	  was	  calculated	  to	  be	  between	  273	  nm	  –	  2.2	  µm.	  Unfortunately,	  
due	  to	  human	  error	  or	  equipment	  malfunction,	  the	  calculated	  film	  thickness	  was	  different	  each	  time	  
that	  the	  biosensor	  was	  fabricated.	  	  
To	  characterize	  the	  polymer	  films,	  scanning	  electron	  microscopy	  (SEM)	  was	  performed.	  The	  
images	  of	  the	  PPY	  and	  PPY-­‐PANI	  films,	  shown	  below	  in	  Figure	  9,	  show	  that	  the	  PPY	  film	  is	  uniformly	  
composed	  of	  many	  small	  bumps,	  with	  pores	  present	  that	  are	  capable	  of	  holding	  LOX.	  Our	  results	  match	  
SEM	  images	  in	  the	  literature.	  The	  PPY-­‐PANI	  film	  had	  a	  very	  thin	  smooth	  layer	  on	  top,	  with	  more	  bumpy	  
topography	  underneath	  this	  thin	  layer.	  The	  thickness	  of	  both	  films	  was	  found	  to	  be	  greater	  than	  
expected,	  with	  a	  thickness	  between	  10-­‐40	  μm	  (data	  not	  shown)	  that	  varied	  in	  different	  regions	  of	  each	  
film. More	  SEM	  images	  can	  be	  seen	  in	  Appendix	  4.	  
	  
Figure	  9:	  SEM	  Images	  of	  Polymer	  Coatings	  
SEM	  images	  of	  PPY	  (left)	  and	  PPY-­‐PANI	  films	  (right).	  Magnification=2500x.	  
	  
To	  select	  a	  final	  design	  from	  our	  design	  alternatives,	  different	  polymer	  films	  were	  tested	  with	  1	  
mM	  lactate	  to	  test	  their	  current	  output.	  It	  was	  found	  that	  the	  PPY-­‐PANI	  film	  (PPY	  on	  bottom,	  PANI	  on	  














































top)	  had	  the	  highest	  current	  output,	  as	  seen	  in	  Figures	  10	  and	  11.	  Believing	  that	  this	  would	  result	  in	  a	  
more	  sensitive	  and	  responsive	  biosensor,	  we	  chose	  to	  do	  all	  further	  tests	  with	  a	  PPY-­‐PANI	  film.	  
	  
Figure	  10:	  Amperometry	  Results	  




















Figure	  11:	  Cyclic	  Voltammetry	  Results	  
Cyclic	  Voltammetry	  curves	  produced	  from	  testing	  the	  GCE,	  PPY	  film,	  PANI	  film,	  PPY-­‐PANI	  film,	  and	  PANI-­‐PPY	  film	  
in	  1	  mM	  lactate	  as	  the	  voltage	  was	  cycled	  from	  -­‐0.4V	  to	  +0.6V.	  
	  
Another	  step	  in	  optimizing	  the	  biosensor	  was	  to	  attach	  the	  enzyme,	  lactate	  oxidase	  (LOX),	  to	  the	  
biosensor.	  Early	  results	  showed	  that	  when	  the	  lactate	  oxidase	  was	  simply	  left	  to	  dry	  and	  adsorb	  onto	  a	  
polymer	  film,	  the	  current	  response	  of	  the	  biosensor	  to	  lactate	  decreased	  dramatically	  after	  every	  test.	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This	  was	  most	  likely	  due	  to	  the	  LOX	  leaching	  off	  of	  the	  biosensor	  into	  the	  lactate	  solution.	  Because	  the	  
biosensor	  needs	  to	  work	  repeatedly	  for	  a	  long	  period	  of	  time,	  we	  chose	  to	  crosslink	  the	  lactate	  oxidase	  
to	  the	  polymer	  film	  with	  glutaraldehyde.	  Glutaraldehyde	  has	  the	  ability	  to	  bind	  to	  two	  amine	  groups,	  
which	  allows	  it	  to	  crosslink	  the	  LOX	  to	  PPY	  and	  PANI,	  both	  of	  which	  contain	  amine	  groups.	  Not	  only	  did	  
crosslinking	  significantly	  prevent	  the	  decrease	  in	  current	  over	  time,	  but	  it	  also	  improved	  the	  current	  
response	  as	  a	  whole,	  because	  more	  of	  the	  LOX	  stayed	  on	  the	  biosensor	  after	  the	  initial	  rinse	  step.	  
Figures	  12	  and	  13	  show	  the	  difference	  that	  crosslinking	  made	  on	  a	  PPY-­‐LOX	  iteration	  of	  the	  biosensor.	  
	  
Figure	  12:	  Amperometry	  Curves	  Comparing	  Addition	  of	  Glutaraldehyde	  



















Amperometry	  -­‐	  Crosslinking	  
PPY-­‐LOX	  not	  crosslinked	  
PPY-­‐LOX	  Crosslinked	  with	  
Glutaraldehyde	  




Figure	  13:	  Cyclic	  Voltammetry	  Curves	  Comparing	  Addition	  of	  Glutaraldehyde	  
Cyclic	  Voltammetry	  curves	  for	  PPY-­‐LOX	  with	  and	  without	  glutaraldehyde	  crosslinking	  in	  1	  mM	  lactate.	  
To	  test	  the	  current	  response	  of	  the	  final	  biosensor	  design	  to	  different	  lactate	  concentrations	  
present	  in	  PBS,	  we	  performed	  amperometry	  for	  3	  trials	  of	  300	  seconds	  for	  each	  of	  the	  following	  lactate	  
concentrations:	  0.05	  mM,	  0.1	  mM,	  1	  mM,	  5	  mM,	  10	  mM,	  17.5	  mM,	  25	  mM.	  	  The	  results	  of	  these	  tests	  
can	  be	  seen	  in	  Figure	  14.	  The	  steady-­‐state	  current	  values	  (taken	  at	  t=300s)	  for	  each	  lactate	  
concentration	  were	  plotted	  to	  create	  a	  standard	  curve	  of	  current	  vs	  concentration,	  shown	  in	  Figure	  15.	  
A	  linear	  trendline	  was	  fitted	  to	  this	  data,	  although	  the	  R2	  value	  was	  only	  0.78.	  The	  trendline	  shows	  that	  
with	  increasing	  lactate	  concentration,	  there	  is	  a	  decrease	  in	  biosensor	  current.	  This	  is	  different	  than	  
expected.	  As	  more	  lactate	  would	  be	  broken	  down	  by	  the	  biosensor,	  we	  would	  expect	  that	  more	  


























Figure	  14:	  Amperometry	  Results	  for	  PPY-­‐PANI-­‐LOX	  Crosslinked	  
Amperometry	  curves	  for	  the	  final	  design	  (PPY-­‐PANI-­‐LOX	  crosslinked)	  for	  0.05	  mM,	  0.1	  mM,	  1	  mM,	  10	  mM,	  17.5	  
mM,	  25	  mM	  of	  lactate.	  
	  
Figure	  15:	  Steady-­‐State	  Current	  for	  Lactate	  Concentrations	  



































y	  =	  -­‐6E-­‐10x	  +	  4E-­‐08	  



























ConcentraWon	  of	  Lactate	  (mM)	  
Final	  Design	  -­‐	  Standard	  Curve	  of	  
Current	  vs	  Lactate	  ConcentraWon	  
(StaWc	  TesWng)	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To	  test	  the	  efficacy	  of	  the	  biosensor	  in	  dynamic	  conditions,	  as	  it	  will	  be	  used	  in	  vivo,	  different	  
volumes	  of	  a	  25	  mM	  lactate	  solution	  were	  added	  every	  100s	  to	  a	  solution	  that	  initially	  consisted	  only	  of	  
PBS	  as	  amperometry	  was	  performed.	  Table	  2	  shows	  the	  addition	  of	  lactate	  over	  time	  and	  the	  resultant	  
lactate	  concentration.	  The	  data	  for	  the	  dynamic	  testing	  is	  shown	  in	  Figure	  16	  reveals	  that	  the	  biosensor	  
has	  a	  fast	  response	  time,	  with	  changes	  in	  current	  happening	  immediately	  after	  the	  addition	  of	  lactate.	  A	  
standard	  curve	  of	  steady-­‐state	  current	  as	  a	  function	  of	  lactate	  concentration	  was	  created	  for	  this	  data	  
set,	  as	  seen	  in	  Figure	  17.	  As	  was	  seen	  with	  the	  static	  testing	  of	  various	  lactate	  concentrations,	  the	  
magnitude	  of	  the	  current	  decreased	  as	  a	  function	  of	  increased	  lactate	  concentration.	  Again,	  this	  is	  not	  
what	  was	  expected,	  and	  further	  testing	  should	  be	  done	  to	  explain	  why	  this	  current	  trend	  is	  observed.	  	  
Table	  2:	  Lactate	  Concentration	  Test	  over	  Time	  
The	  volume	  of	  25	  mM	  lactate	  solution	  added	  at	  each	  time	  point,	  with	  the	  resultant	  lactate	  concentration.	  
	  






New	  Concentration	  (mM)	  
1	   -­‐-­‐	   0	   5	   0	  
2	   0.2	  mL	  of	  25	  mM	  lactate	   0.000005	   5.2	   0.96	  
3	   0.4	  mL	  of	  25	  mM	  lactate	   0.000015	   5.6	   2.68	  
4	   0.8	  mL	  of	  25	  mM	  lactate	   0.000035	   6.4	   5.47	  
5	   0.8	  mL	  of	  25	  mM	  lactate	   0.000055	   7.2	   7.43	  
6	   0.8	  mL	  of	  25	  mM	  lactate	   0.000075	   8	   9.38	  
	  




Figure	  16:	  Current	  Response	  with	  Addition	  of	  Lactate	  over	  Time	  
The	  current	  response	  to	  an	  increase	  in	  lactate	  concentration	  over	  time.	  
	  
	  
Figure	  17:	  Standard	  Curve	  with	  Addition	  of	  Lactate	  over	  Time	  
The	  standard	  curve	  of	  steady-­‐state	  current	  as	  a	  function	  of	  lactate	  concentration,	  tested	  in	  a	  dynamic	  system.	  
	  
Media	  that	  was	  collected	  after	  culturing	  with	  U87mg	  human	  glioblastoma	  cells	  for	  48	  hours	  was	  
tested	  with	  both	  the	  lactate	  ELISA	  and	  the	  biosensor	  in	  order	  to	  compare	  the	  biosensor’s	  efficacy	  at	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  Lactate	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  Time	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  -­‐4E-­‐09x	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  5E-­‐08	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highest	  lactate	  concentration	  at	  1.2	  mM.	  Although	  the	  plates	  containing	  1	  million	  cells	  was	  expected	  to	  
have	  the	  highest	  lactate	  concentration,	  this	  can	  be	  explained	  by	  the	  general	  unhealthy	  appearance	  of	  
the	  plates	  containing	  1	  million	  cells	  after	  48	  hours	  of	  culture.	  Redoing	  this	  experiment	  may	  lead	  to	  
healthier	  cells,	  and	  therefore	  the	  media	  containing	  1	  million	  cells	  would	  have	  the	  highest	  lactate	  
concentration.	  When	  amperometry	  tests	  were	  performed	  with	  the	  biosensor	  of	  the	  media	  (3	  samples	  of	  
media	  per	  cell	  number),	  it	  was	  found	  that	  similarly	  to	  the	  ELISA	  results,	  that	  there	  was	  a	  higher	  current	  
for	  the	  media	  containing	  500,000	  cells.	  However,	  when	  we	  input	  the	  current	  values	  into	  the	  equation	  for	  
the	  standard	  curve	  shown	  in	  Figure	  17,	  negative	  values	  for	  lactate	  concentration	  were	  calculated.	  This	  is	  
obviously	  unreasonable.	  This	  can	  be	  explained	  by	  the	  fact	  that	  the	  magnitudes	  of	  the	  currents	  for	  the	  
biosensor	  tested	  in	  media	  were	  much	  higher	  than	  those	  tested	  in	  PBS.	  This	  would	  indicate	  that	  there	  are	  
some	  non-­‐specific	  interactions	  with	  other	  molecules	  in	  the	  cell	  media	  that	  are	  causing	  more	  electrons	  to	  
be	  created	  and	  flow	  through	  the	  biosensor.	  
Table	  3:	  Lactate	  Concentrations	  of	  Glioblastoma	  Cells	  
The	  average	  current	  read	  by	  the	  biosensor,	  the	  average	  lactate	  concentration	  calculated	  using	  the	  standard	  
curve,	  and	  the	  actual	  lactate	  concentration	  measured	  with	  an	  ELISA	  for	  media	  samples	  containing	  1,000,000,	  







	   Average	  Current	  (A)	   Average	  Lactate	  Concentration	  
Calculated	  (mM)	  
1,000,000	   0.93	  ±	  0.25	   	   2.36E-­‐07	  ±	  5.5E-­‐8	   -­‐46.5	  
500,000	   1.24	  ±	  0.07	   	   2.70E-­‐07	  ±	  4.4E-­‐8	   -­‐55.1	  
100,000	   0.31±	  0.008	   	   1.35E-­‐07±	  3.4E-­‐8	   -­‐21.2	  
	  
The	  performance	  of	  the	  biosensor	  design	  developed	  by	  this	  MQP	  was	  compared	  to	  the	  
performance	  of	  a	  PPY-­‐LOX	  (not	  crosslinked)	  biosensor,	  which	  the	  previous	  MQP	  designed,	  and	  a	  
Chitosan-­‐LOX	  biosensor,	  which	  uses	  a	  non-­‐conductive	  polymer.	  Both	  amperometry	  (Figure	  18)	  and	  cyclic	  
voltammetry	  (Figure	  19)	  tests	  were	  performed	  in	  order	  to	  compare	  the	  different	  biosensors.	  It	  was	  
found	  that	  the	  PPY-­‐PANI-­‐LOX	  (crosslinked)	  design	  developed	  by	  this	  MQP	  had	  a	  higher	  current	  response	  
than	  the	  other	  biosensor	  designs.	  The	  improvement	  of	  the	  current	  biosensor	  over	  that	  of	  the	  previous	  
MQP	  suggests	  that	  the	  addition	  of	  the	  PANI	  and	  the	  crosslinking	  of	  the	  enzyme	  to	  the	  polymers	  were	  
beneficial	  to	  biosensor	  performance.	  The	  improvement	  of	  the	  current	  biosensor	  over	  the	  Chitosan-­‐LOX	  
design	  shows	  the	  importance	  of	  conductive	  polymers	  in	  our	  design.	  	  


























































Figure	  18:	  Amperometry	  Comparisons	  of	  Different	  Biosensor	  Designs	  
Amperometry	  curves	  for	  the	  PPY-­‐LOX	  (previous	  MQP’s	  design),	  PPY-­‐PANI-­‐LOX,	  and	  Chitosan-­‐LOX	  designed	  




















Figure	  19:	  Cyclic	  Voltammetry	  Comparisons	  of	  Different	  Biosensor	  Designs	  
Cyclic	  voltammetry	  curves	  for	  the	  PPY-­‐LOX	  (previous	  MQP’s	  design),	  PPY-­‐PANI-­‐LOX,	  and	  Chitosan-­‐LOX	  designed	  
biosensors	  in	  1	  mM	  lactate.	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7.  Analysis   and  Discussion  
In	  order	  to	  determine	  what	  concentration	  of	  lactate	  the	  biosensor	  must	  be	  able	  to	  measure,	  the	  
amount	  of	  lactate	  produced	  by	  human	  glioblastoma	  cells	  was	  measured	  using	  a	  lactate	  colorimetric	  
assay	  (Sigma-­‐Aldrich).	  GBM	  tumors	  will	  have	  cell	  numbers	  in	  the	  millions,	  so	  the	  biosensor	  must	  be	  
able	  to	  detect	  lactate	  levels	  on	  the	  millimolar	  scale.	  The	  biosensor	  was	  tested	  at	  lactate	  
concentrations	  ranging	  from	  0.05	  mM	  to	  25	  mM	  but	  was	  focused	  in	  the	  1	  to	  10	  mM	  range,	  which	  is	  
an	  appropriate	  range	  to	  monitor	  tumor	  size	  in	  GBM	  patients.	  
In	  order	  to	  optimize	  the	  polymer	  films	  of	  the	  biosensor,	  a	  variety	  of	  fabrication	  methods	  were	  
tested.	  For	  PPY	  films,	  the	  galvanostatic	  method	  produced	  a	  film	  with	  the	  highest	  current	  response	  
and	  created	  a	  uniform	  film	  on	  the	  surface	  of	  the	  electrode.	  Because	  the	  current	  measured	  by	  the	  
biosensor	  is	  so	  small,	  it	  was	  necessary	  to	  choose	  the	  design	  with	  the	  highest	  current	  response.	  In	  the	  
fabrication	  of	  the	  PANI	  film,	  there	  was	  variation	  in	  film	  thickness.	  This	  could	  be	  due	  to	  
equipment/software	  malfunction	  or	  human	  error.	  In	  order	  to	  accurately	  determine	  the	  thickness	  of	  
the	  PANI	  layer,	  SEM	  was	  performed.	  	  
SEM	  images	  were	  taken	  of	  the	  PPY	  and	  PPY-­‐PANI	  coatings.	  The	  PPY	  film	  looks	  similar	  to	  other	  
published	  images	  of	  PPY	  coatings	  (Liu	  et	  al.,	  2009)	  and	  has	  pores	  of	  0.5	  –	  5	  µm,	  which	  can	  entrap	  
lactate	  oxidase.	  The	  PPY-­‐PANI	  film	  has	  a	  very	  thin,	  smooth	  layer.	  Through	  cracks	  in	  this	  layer,	  pores	  
and	  other	  topographical	  features	  can	  be	  seen.	  The	  SEM	  images	  were	  used	  to	  determine	  film	  
thickness	  and	  the	  films	  were	  much	  thicker	  than	  expected.	  The	  PPY	  film	  was	  expected	  to	  be	  100	  nm	  
while	  the	  PPY-­‐PANI	  was	  between	  200	  nm	  and	  2	  µm.	  The	  actual	  thickness	  of	  the	  films	  was	  10-­‐40	  µm.	  
The	  high	  film	  thickness	  can	  interfere	  with	  the	  ability	  of	  electrons	  to	  reach	  the	  electrode	  surface	  and	  
decrease	  the	  current	  measured	  by	  the	  biosensor.	  In	  order	  to	  optimize	  the	  biosensor,	  the	  film	  
thickness	  must	  be	  reduced.	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Preliminary	  testing	  at	  1	  mM	  lactate	  was	  performed	  on	  a	  variety	  of	  design	  alternatives	  in	  order	  to	  
determine	  which	  one	  had	  the	  highest	  response.	  Both	  PPY	  and	  PANI	  individually	  and	  PANI-­‐PPY	  had	  a	  
current	  response	  comparable	  to	  a	  plain	  GCE.	  The	  PPY-­‐PANI	  film	  had	  a	  much	  higher	  current	  response	  
than	  the	  other	  alternatives,	  which	  means	  that	  more	  electrons	  reached	  the	  GCE	  surface.	  This	  
suggests	  that	  the	  film	  promoted	  electron	  transfer	  to	  the	  electrode	  surface	  rather	  than	  into	  the	  
surrounding	  solution	  and	  will	  make	  a	  more	  sensitive	  biosensor	  with	  a	  shorter	  response	  time.	  
	   	   The	  enzyme	  lactate	  oxidase	  catalyzes	  the	  breakdown	  of	  lactate	  into	  hydrogen	  peroxide	  and	  
eventually	  free	  electrons	  and	  shortens	  the	  biosensor	  response	  time.	  When	  lactate	  oxidase	  was	  
dropped	  on	  the	  polymer	  film	  and	  allowed	  to	  dry,	  the	  current	  response	  quickly	  decreased	  in	  
consecutive	  trials.	  This	  is	  due	  to	  excess	  lactate	  oxidase	  and	  the	  enzyme	  diffusing	  out	  of	  the	  polymer	  
film.	  The	  biosensor	  was	  not	  rinsed	  sufficiently	  and	  excess	  lactate	  oxidase	  on	  the	  biosensor	  surface	  
was	  reacting	  in	  the	  first	  trial	  but	  was	  not	  present	  in	  the	  subsequent	  trials,	  causing	  a	  decreased	  
current	  response.	  Because	  the	  enzyme	  was	  not	  bound	  to	  the	  polymers,	  it	  was	  easily	  able	  to	  diffuse	  
from	  the	  film,	  which	  decreases	  the	  biosensor	  current	  response	  in	  subsequent	  trials.	  In	  order	  to	  
maintain	  a	  constant	  current	  response	  and	  solve	  these	  issues,	  the	  lactate	  oxidase	  was	  crosslinked	  to	  
the	  polymer	  surface	  using	  glutaraldehyde	  and	  the	  number	  and	  length	  of	  rinses	  was	  increased	  to	  
three,	  ten-­‐minute	  rinses.	  Once	  these	  adjustments	  were	  made,	  the	  current	  response	  was	  constant	  in	  
multiple	  consecutive	  trials.	  	  
The	  final	  design	  was	  tested	  at	  different	  lactate	  concentrations	  ranging	  from	  0.05	  to	  25	  mM	  
lactate.	  The	  current	  response	  from	  these	  lactate	  concentrations	  were	  used	  to	  create	  a	  standard	  
curve.	  The	  standard	  curve	  showed	  a	  slight	  trend	  of	  decreasing	  current	  with	  increasing	  lactate	  
concentration.	  It	  is	  expected	  that	  the	  current	  would	  increase	  with	  increasing	  lactate	  concentration.	  
This	  experiment	  was	  only	  performed	  once	  on	  properly	  calibrated	  equipment	  at	  the	  University	  of	  
Connecticut,	  so	  repetition	  of	  this	  test	  is	  needed	  in	  order	  to	  verify	  this	  result.	  
	   	   Project	  BME-­‐AJ1-­‐SZ1	  
57	  
	  
The	  response	  of	  the	  biosensor	  was	  compared	  to	  the	  response	  of	  other	  similar	  biosensors.	  The	  
final	  design,	  and	  another	  design	  based	  on	  PPY	  had	  much	  higher	  current	  responses	  than	  a	  similar	  
design	  with	  a	  chitosan	  and	  lactate	  oxidase	  film.	  Chitosan	  is	  a	  nonconductive	  polymer,	  so	  electrons	  
will	  meet	  more	  resistance	  and	  fewer	  electrons	  reached	  the	  electrode	  surface.	  The	  final	  design	  had	  a	  
higher	  current	  response	  than	  the	  PPY-­‐LOX	  film,	  designed	  and	  tested	  by	  a	  previous	  project	  team	  
(Anglin	  et	  al.,	  2013).	  	  
The	  response	  of	  the	  biosensor	  was	  also	  tested	  over	  time	  in	  changing	  lactate	  concentrations.	  
When	  more	  lactate	  was	  added	  to	  the	  system,	  a	  current	  spike	  occurs,	  meaning	  the	  biosensor	  is	  able	  
to	  detect	  the	  addition	  of	  more	  lactate.	  After	  the	  initial	  spike	  when	  lactate	  is	  added,	  the	  current	  
response	  decreases.	  The	  biosensor	  is	  successful	  at	  detecting	  the	  change	  in	  lactate	  concentration	  in	  
dynamic	  testing.	  In	  the	  future,	  when	  this	  biosensor	  is	  implanted	  into	  the	  body,	  it	  will	  be	  exposed	  to	  
a	  dynamic	  system	  and	  it	  is	  important	  that	  the	  biosensor	  can	  respond	  and	  measure	  changing	  lactate	  
concentrations.	  
The	  concentration	  of	  lactate	  produced	  by	  human	  glioblastoma	  cells	  was	  measured	  using	  an	  
ELISA	  kit.	  As	  expected,	  the	  500,000	  cells	  had	  produced	  more	  lactate	  than	  the	  100,000	  cells;	  
however,	  1	  million	  cells	  produced	  slightly	  less	  lactate	  than	  500,000	  cells.	  When	  the	  media	  was	  
collected	  from	  culture	  after	  48	  hours,	  the	  1	  million	  cells	  did	  not	  look	  healthy,	  explaining	  why	  they	  
produced	  less	  lactate.	  The	  current	  response	  of	  the	  biosensor	  in	  these	  media	  samples	  was	  also	  
tested.	  The	  500,000	  cells	  had	  the	  highest	  current	  output	  because	  there	  was	  the	  highest	  lactate	  
concentration.	  When	  the	  equation	  from	  the	  standard	  curve	  was	  used	  to	  calculate	  the	  lactate	  
concentration,	  the	  values	  were	  negative,	  which	  is	  not	  possible.	  We	  believe	  this	  is	  due	  to	  non-­‐specific	  
reactions	  between	  analytes	  in	  the	  media	  and	  the	  biosensor.	  The	  culture	  media	  contains	  glutamate	  
and	  other	  analytes	  that	  can	  also	  be	  broken	  down	  into	  hydrogen	  peroxide	  and	  eventually	  electrons.	  
This	  may	  explain	  why	  the	  current	  output	  was	  an	  order	  of	  magnitude	  higher	  when	  tested	  in	  cell	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media	  than	  when	  tested	  in	  different	  lactate	  solutions	  in	  PBS.	  In	  order	  to	  reduce	  this	  interference,	  in	  
the	  future	  adding	  more	  lactate	  oxidase	  to	  the	  biosensor	  will	  increase	  the	  biosensor’s	  specificity.	  	  
This	  biosensor	  system	  created	  will	  greatly	  benefit	  GBM	  patients	  economically.	  Current	  
monitoring	  methods	  cost	  thousands	  of	  dollars	  per	  test	  so	  it	  is	  not	  feasible	  to	  frequently	  monitor	  
lactate	  levels.	  Although	  the	  biosensor	  will	  also	  be	  on	  the	  order	  of	  thousands	  of	  dollars,	  it	  will	  allow	  
for	  frequent	  monitoring	  over	  the	  period	  of	  months	  to	  years,	  reducing	  the	  overall	  cost	  of	  monitoring	  
GBM	  significantly.	  
The	  biosensor	  is	  feasible	  to	  manufacture	  in	  large	  quantities.	  The	  process	  of	  depositing	  the	  film	  
on	  the	  electrode	  surface	  is	  fairly	  simple	  and	  does	  not	  require	  excess	  time	  or	  abnormal	  conditions.	  
However	  once	  the	  lactate	  oxidase	  is	  deposited,	  the	  sensor	  must	  be	  stored	  at	  4⁰C	  or	  below.	  Although	  
the	  design	  is	  currently	  simple	  to	  manufacture,	  more	  problems	  may	  be	  encountered	  in	  the	  
miniaturization	  process.	  
Excess	  lactate	  is	  produced	  by	  all	  forms	  of	  cancer,	  so	  once	  optimized	  this	  technology	  can	  be	  
applied	  to	  monitoring	  any	  form	  of	  cancer.	  Current	  monitoring	  methods	  are	  done	  infrequently,	  
usually	  approximately	  every	  six	  months.	  During	  that	  time,	  a	  recurring	  tumor	  could	  grow	  
substantially	  and	  become	  fatal.	  The	  biosensor	  allows	  physicians	  and	  patients	  to	  monitor	  lactate	  
levels	  constantly	  and	  find	  recurrences	  right	  away.	  While	  right	  now,	  the	  output	  of	  biosensor	  is	  
measured	  by	  a	  computer,	  in	  the	  future,	  the	  output	  could	  be	  sent	  to	  a	  smart	  watch,	  a	  cell	  phone	  app	  
or	  any	  other	  device.	  The	  biosensor	  can	  be	  used	  to	  monitor	  the	  efficacy	  of	  different	  treatments	  and	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8.  Recommendations  
In	  order	  to	  optimize	  the	  biosensor,	  the	  film	  uniformity	  must	  be	  improved	  and	  the	  thickness	  
decreased.	  To	  improve	  film	  uniformity,	  the	  team	  recommends	  that	  a	  stir	  bar	  be	  added	  to	  the	  solution	  
during	  deposition.	  The	  pyrrole	  or	  aniline	  is	  not	  soluble	  in	  PBS	  and	  adding	  a	  stir	  bar	  would	  ensure	  
complete	  mixing	  of	  the	  two	  liquids.	  In	  order	  to	  decrease	  the	  thickness	  of	  the	  polypyrrole	  film,	  the	  
polymerization	  time	  could	  be	  shortened	  or	  less	  pyrrole	  be	  added.	  In	  order	  to	  decrease	  the	  thickness	  of	  
the	  PANI	  layer,	  fewer	  cycles	  should	  be	  performed	  during	  electrochemical	  deposition	  or	  less	  aniline	  
should	  be	  polymerized.	  	  
Throughout	  the	  project,	  the	  team	  encountered	  some	  setbacks.	  The	  team	  researched	  and	  completed	  
preliminary	  testing	  on	  many	  design	  alternatives.	  Less	  preliminary	  testing	  would	  have	  allowed	  the	  team	  
to	  choose	  the	  final	  design	  and	  collect	  more	  data	  to	  validate	  this	  design.	  In	  order	  to	  avoid	  setbacks	  and	  
progress	  further,	  it	  is	  also	  recommended	  that	  all	  equipment	  be	  properly	  calibrated.	  Due	  to	  time	  
constraints,	  some	  tests	  were	  only	  completed	  once.	  These	  tests	  should	  be	  performed	  in	  triplicate	  in	  
order	  to	  ensure	  the	  resulting	  data	  is	  validated.	  	  
Although	  the	  lactate	  biosensor	  created	  for	  this	  project	  was	  able	  to	  detect	  changing	  levels	  of	  lactate	  
concentration	  and	  detect	  the	  lactate	  concentration	  in	  media,	  we	  were	  unable	  to	  validate	  the	  biosensor’s	  
effectiveness	  completely.	  Biocompatibility	  testing	  in	  vitro	  should	  be	  done	  to	  ensure	  that	  the	  device	  is	  
not	  cytotoxic.	  Additionally,	  the	  biosensor	  should	  be	  kept	  in	  aqueous	  conditions	  at	  37	  degrees	  Celsius	  for	  
a	  period	  of	  at	  least	  8	  weeks	  to	  test	  the	  overall	  function	  of	  the	  biosensor	  over	  time	  in	  physiological	  
conditions.	  This	  is	  important	  because	  the	  biosensor	  will	  need	  to	  function	  accurately	  for	  a	  period	  of	  
several	  months	  in	  order	  to	  be	  effective	  as	  a	  monitoring	  device.	  To	  evaluate	  the	  selectivity	  of	  the	  
biosensor,	  lactate	  solutions	  that	  contain	  molecules	  such	  as	  glucose	  or	  ascorbic	  acid	  should	  be	  tested	  in	  
order	  to	  ensure	  that	  the	  current	  produced	  by	  the	  biosensor	  is	  only	  a	  result	  of	  lactate	  breakdown,	  not	  
the	  breakdown	  of	  other	  molecules.	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This	  biosensor	  should	  also	  be	  redesigned	  with	  glutamate	  oxidase	  replacing	  the	  lactate	  oxidase,	  so	  
that	  the	  concentration	  of	  glutamate	  could	  also	  be	  tested.	  Glutamate	  is	  also	  produced	  in	  higher	  
quantities	  by	  glioblastoma	  cells,	  and	  could	  also	  serve	  as	  an	  indicator	  of	  tumor	  progression.	  The	  lactate	  
and	  glutamate	  biosensors	  could	  be	  combined	  into	  a	  dual	  biosensor	  system	  that	  could	  be	  used	  more	  
effectively	  to	  monitor	  glioblastoma	  tumor	  progression	  as	  a	  function	  of	  lactate	  and	  glutamate	  
production.	  	  
In	  order	  for	  this	  biosensor	  to	  be	  a	  device	  that	  could	  be	  used	  in	  vivo,	  miniaturization	  will	  be	  
necessary.	  The	  design	  would	  need	  to	  be	  optimized	  in	  order	  to	  work	  most	  effectively	  on	  a	  smaller	  
electrode	  surface.	  A	  device	  that	  could	  export	  the	  biosensor’s	  data,	  through	  WiFi	  or	  other	  means,	  to	  a	  
physician’s	  computer	  or	  mobile	  device,	  would	  be	  necessary	  in	  order	  for	  the	  biosensor	  to	  be	  used	  as	  an	  
implantable	  medical	  device.	  Once	  the	  addition	  of	  a	  data	  reporter	  was	  validated,	  the	  biosensor	  could	  be	  
tested	  in	  vivo	  on	  a	  small	  animal	  model.	  	  	  
9.  Conclusions  
A	  lactate	  biosensor	  was	  designed	  and	  tested	  to	  monitor	  tumor	  size	  in	  GBM	  patients.	  Because	  GBM	  is	  
so	  aggressive,	  it	  is	  important	  to	  be	  able	  to	  frequently	  monitor	  tumor	  progression	  to	  determine	  if	  
treatments	  are	  effective.	  The	  current	  monitoring	  methods	  are	  not	  appropriate	  for	  frequent	  use	  because	  
they	  detect	  large	  tumors	  and	  are	  very	  expensive.	  	  
The	  lactate	  biosensor	  is	  able	  to	  detect	  changes	  in	  current	  with	  changing	  lactate	  concentration	  and	  
has	  an	  almost	  instantaneous	  response	  of	  less	  than	  one	  second.	  The	  low	  cost	  will	  allow	  GBM	  patients	  
more	  constant	  monitoring	  of	  lactate	  levels	  and	  will	  allow	  physicians	  to	  detect	  tumor	  recurrence	  early.	  	  	  
Although	  the	  biosensor	  shows	  potential,	  many	  issues	  must	  be	  overcome	  before	  it	  can	  be	  
implemented	  in	  GBM	  patients.	  Validation	  of	  the	  biosensor	  was	  hindered	  by	  equipment	  malfunction,	  so	  
more	  testing	  is	  needed	  to	  ensure	  that	  lactate	  levels	  are	  being	  measured	  accurately.	  Further	  research	  is	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needed	  to	  optimize	  the	  biosensor	  for	  long-­‐term	  use,	  on	  the	  timeframe	  of	  months	  to	  years,	  at	  
physiological	  conditions	  and	  miniaturizing	  the	  device	  to	  make	  it	  implantable.	  The	  biosensor	  is	  early	  in	  
the	  design	  and	  validation	  process	  but	  with	  further	  research	  this	  technology	  can	  be	  applied	  to	  all	  types	  of	  
cancer.	  	  
An	  early-­‐stage	  lactate	  biosensor	  was	  created	  to	  monitor	  tumor	  size	  in	  GBM	  patients.	  Although	  this	  
design	  requires	  more	  troubleshooting	  and	  validation,	  it	  shows	  promise.	  Once	  optimized,	  this	  system	  can	  
be	  applied	  to	  not	  only	  monitoring	  GBM,	  but	  also	  monitoring	  all	  forms	  of	  cancer.	  This	  technology	  has	  the	  
potential	  to	  revolutionize	  tumor	  monitoring	  for	  cancer	  patients	  and	  greatly	  reduce	  medical	  costs.	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Appendix  1  -­‐   Experimental   Protocols   
Culturing  Cells   
U87mg	  human	  glioblastoma	  cells	  were	  cultured	  in	  media	  containing	  DMEM,	  10%Fetal	  Bovine	  Serum,	  1%	  
Pen-­‐Strep,	  1%	  NEAA	  in	  1-­‐5	  mL	  of	  media	  for	  48	  hours	  before	  the	  media	  was	  removed	  for	  use	  in	  testing.	  
Assays  
Lactate	  Assay	  
Using	  the	  protocol	  found	  on	  the	  Sigma-­‐Aldrich	  website,	  
http://www.sigmaaldrich.com/content/dam/sigma-­‐aldrich/docs/Sigma/Bulletin/1/mak064bul.pdf,	  a	  
standard	  curve	  ranging	  from	  0-­‐10	  nmol	  was	  created.	  For	  measuring	  the	  concentration	  of	  lactate	  in	  cell	  
media,	  5	  µL	  of	  media	  in	  45	  µL	  of	  buffer	  was	  used	  as	  the	  sample.	  After	  incubation	  with	  the	  reaction	  mix	  
for	  30	  minutes	  at	  room	  temperature,	  the	  absorbance	  of	  each	  well	  was	  measured	  using	  a	  plate	  reader	  at	  
570nm.Based	  on	  the	  equation	  given	  by	  the	  standard	  curve	  (Appendix	  2),	  the	  concentration	  of	  lactate	  
present	  in	  the	  media	  before	  dilution	  could	  be	  calculated.	  	  
Testing  Solutions    
All	  solutions	  were	  made	  of	  lithium	  lactate	  dissolved	  in	  0.01	  M	  PBS.	  All	  solutions	  should	  be	  de-­‐gassed	  by	  
adding	  nitrogen	  gas	  to	  the	  solution	  for	  15	  minutes	  prior	  to	  testing.	  
Amperometry	  
1. Open	  GPES	  software.	  
2. Insert	  working	  electrode	  (glassy	  carbon),	  reference	  electrode	  (Ag/AgCl),	  and	  counter	  
electrode	  (platinum)	  through	  the	  cap	  of	  the	  electrochemical	  cell	  and	  into	  the	  solution	  being	  
tested.	  	  
3. Attach	  the	  red	  wire	  to	  the	  working	  electrode,	  the	  blue	  wire	  to	  the	  reference	  electrode,	  and	  
the	  black	  wire	  to	  the	  counter	  electrode.	  
4. Under	  methods,	  mouse	  over	  to	  chrono	  methods	  >	  0.1s,	  and	  select	  amperometry.	  
5. Select	  the	  following	  settings	  for	  the	  amperometry:	  
a. Potential	  =	  0.2V	  
b. Time=300s	  
Note:	  the	  same	  solution	  was	  tested	  with	  both	  amperometric	  and	  voltammetric	  methods	  for	  each	  trial.	  
Cyclic	  Voltammetry	  
1. Open	  GPES	  software.	  
2. Insert	  working	  electrode	  (glassy	  carbon),	  reference	  electrode	  (Ag/AgCl),	  and	  counter	  
electrode	  (platinum)	  through	  the	  cap	  of	  the	  electrochemical	  cell	  and	  into	  the	  solution	  being	  
tested.	  	  
3. Attach	  the	  red	  wire	  to	  the	  working	  electrode,	  the	  blue	  wire	  to	  the	  reference	  electrode,	  and	  
the	  black	  wire	  to	  the	  counter	  electrode.	  
4. Under	  methods,	  select	  voltammetry	  –	  normal.	  
5. Select	  the	  following	  settings	  for	  the	  cyclic	  voltammetry:	  
a. Number	  of	  cycles=10	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b. Start	  potential=	  -­‐0.4V	  
c. Minimum	  Potential	  =	  -­‐0.4V	  
d. Maximum	  Potential	  =	  +0.6V	  
e. Step	  Potential	  =	  0.00244V	  
f. Scan	  rate	  =	  0.05V/s	  
PPY	  polymerization	  (Li	  et	  al.,	  2005.)	  
1. De-­‐gas	  10	  milliliters	  of	  0.01	  M	  phosphate	  buffered	  saline	  (PBS)	  for	  15	  minutes.	  	  
2. Add	  7	  µL	  of	  pyrrole	  (liquid)	  and	  stir	  rapidly	  with	  pipet	  tip.	  
3. Set	  up	  working	  electrode,	  reference	  electrode,	  and	  counter	  electrode	  (described	  previously)	  and	  
open	  GPES.x	  10	  	  
4. Under	  Methods,	  mouse	  over	  to	  chrono	  methods	  >	  0.1s,	  and	  select	  potentiometry	  
(galvanostatic.)	  
5. Settings	  should	  be	  as	  follows:	  
a. Current	  =	  0.007A	  
b. Time	  =	  120s	  
PANI	  polymerization	  (Gaikwad	  et	  al.,	  2006)	  
1. De-­‐gas	  10	  mL	  of	  0.1	  M	  PBS	  (pH	  3.5).	  
2. Add	  0.5	  mL	  aniline	  to	  10	  mL	  of	  0.1	  M	  PBS.	  	  
3. Set	  up	  working	  electrode,	  reference	  electrode,	  and	  counter	  electrode	  (described	  previously)	  and	  
open	  GPES.	  
4. Under	  Methods,	  select	  cyclic	  voltammetry	  (normal).	  	  
5. Select	  the	  following	  settings	  for	  the	  cyclic	  voltammetry:	  
a. Number	  of	  cycles=10	  
b. Start	  potential=	  0.0V	  
c. Minimum	  Potential	  =	  0.0V	  
d. Maximum	  Potential	  =	  +0.95V	  
e. Step	  Potential	  =	  0.00244V	  
f. Scan	  rate	  =	  0.100	  	  V/s	  
Crosslinking	  Enzyme	  to	  Films	  
1. After	  creating	  the	  desired	  polymer	  films	  using	  the	  protocols	  described	  above,	  add	  5	  µL	  of	  0.1%	  
glutaraldehyde	  on	  top	  of	  the	  polymer	  film.	  Let	  dry	  at	  room	  temperature	  for	  30	  minutes.	  	  
2. Add	  5	  µL	  of	  2.9	  mg/mL	  lactate	  oxidase	  (Sigma)	  on	  top	  of	  the	  polymer-­‐glutaraldehyde	  film.	  Let	  
dry	  at	  room	  temperature	  for	  30	  minutes.	  
3. Rinse	  electrode	  3	  times	  for	  10	  minutes	  each	  in	  0.01	  M	  PBS.	  
4. Store	  in	  fridge	  if	  the	  biosensor	  will	  not	  be	  used	  immediately.	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Appendix  2  –  Lactate  Standard  Curve  
	  
	  
	   	  
y	  =	  0.0105x	  +	  0.0944	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Appendix  4  –  More  SEM  Images  
PPY	  Film	  
	  
PPY-­‐PANI	  Film	  
	  
